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APPLYING LESSONS FROM THE OPIOID ABUSE
EPIDEMIC TO PROTECT CONSUMERS FROM
GRAY MARKET BIOLOGICS
MICHAEL C. BARNES* & STACEY L. WORTHY**
I. INTRODUCTION
Almost 17,000 people die per year of overdoses involving prescrip-
tion opioids,1 controlled substances prescribed to treat pain and addic-
tion.  As such, the Centers for Disease Control and Prevention (“CDC”)
has deemed prescription drug abuse2 a national epidemic.3  In addition
to opioids, several other classes of prescription medications have
become prone to abuse, including stimulants and benzodiazepines.4  As
many as twenty percent of college students have used stimulants at
some point in their studies for nonmedical use,5 and the number of
admissions to substance abuse treatment programs for benzodiazepine
use nearly tripled between 1998 and 2008.6  And in 2011,
* Michael C. Barnes, Esq. is the managing attorney at DCBA Law & Policy and the
executive director of the Center for Lawful Access and Abuse Deterrence (CLAAD).
** Stacey L. Worthy, Esq. is an associate attorney at DCBA Law & Policy and the
director of public policy for the Alliance for the Adoption of Innovations in Medicine
(Aimed Alliance).
1. Press Release, U.S. CTRS. FOR DISEASE CONTROL & PREVENTION, Opioids Drive
Continued Increase in Drug Overdose Deaths (Feb. 20, 2013), http://www.cdc.gov/
media/releases/2013/p0220_drug_overdose_deaths.html.
2. “Prescription drug abuse,” as used herein, is “the intentional self-administration
of a medication for a nonmedical purpose such as ‘getting high.’”  This “includes all
degrees of medication use with the intention of experiencing a high, from teens swallow-
ing pills from medicine cabinets to inveterate addicts ‘shooting’ morphine.  Abuse and
nonmedical use are synonymous for the purpose of this [A]rticle.” CENT. FOR LAWFUL
ACCESS & ABUSE DETERRENCE, NATIONAL PRESCRIPTION DRUG ABUSE PREVENTION STRATEGY
7 (2010) [hereinafter NATIONAL STRATEGY].
3. Policy Impact: Prescription Painkiller Overdoses, CDC, http://www.cdc.gov/homean-
drecreationalsafety/rxbrief/ (last updated July 2, 2013). The CDC defines “epidemic” as
“[t]he occurrence of disease within a specific geographical area or population that is in
excess of what is normally expected.”  Glossary, CDC, http://www.cdc.gov/vaccines/
about/terms/glossary.htm#e (last updated July 8, 2013).
4. Ryan Jaslow, New U.S. Drug Survey: Marijuana and Heroin Increasing, CBS NEWS
(Sept. 4, 2013, 4:28 PM), http://www.cbsnews.com/news/new-us-drug-survey-marijuana-
and-heroin-increasing/.
5. Charles Corra, Abusing Prescription Adderall Hurts Those with ADHD, THE DAILY
ATHENAEUM (Mar. 24, 2010, 12:00 AM), http://www.thedaonline.com/article_5a527a21-
9605-5538-86b8-654b3c047a29.html.
6. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., THE TEDS REPORT: SUB-
STANCE ABUSE TREATMENT ADMISSIONS FOR ABUSE OF BENZODIAZEPINES 5 (2011), available at
http://store.samhsa.gov/product/Substance-Abuse-Treatment-Admissions-for-Abuse-of-
Benzodiazepines/TEDS11-0602.
375
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benzodiazepines caused the most prescription drug overdose deaths in
Georgia.7
To prevent prescription drug abuse, the White House and various
US agencies have developed policies,8 states have enacted legislation,
and both federal and state governments have begun to vigorously
enforce controlled substance regulations.9  These efforts are beginning
to yield results.10
One approach to reducing controlled substance abuse has been to
encourage the development of alternative medications that cannot be
abused as easily, including biologics.11   Biologics are pharmaceutical
products made through a biological process rather than being chemi-
cally synthesized.12  Although relatively new in comparison to tradi-
tional small molecule, chemical drugs, the market for biologics is
7. Press Release, Georgia Bureau of Investigation, Deaths Related to Prescription
Drug Overdoses Decline in 2011 (Aug. 14, 2012), http://gbi.georgia.gov/press-releases/
2012-08-14/deaths-related-prescription-drug-overdoses-decline-2011.
8. Agencies advocating for opioid abuse prevention and treatment include the
Office of National Drug Control Policy, the National Institute on Drug Abuse, the U.S.
Food and Drug Administration, and the Substance Abuse and Mental Health Services
Administration, to name a few. See OFFICE OF NAT’L DRUG CONTROL POLICY, NATIONAL
DRUG CONTROL STRATEGY (2013), http://www.whitehouse.gov/sites/default /files/
ondcp/policy-and-research/ndcs_2013.pdf; NAT’L INST. ON DRUG ABUSE, PRINCIPLES OF
DRUG ADDICTION TREATMENT: A RESEARCH-BASED GUIDE (THIRD EDITION), available at
http://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-
based-guide-third-edition/principles-effective-treatment; Press Release, U.S. FOOD &
DRUG ADMIN., FDA Approves Abuse-Deterrent Labeling for Reformulated OxyContin
(Apr. 16, 2013), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements /
ucm348252.htm; Prevent Prescription Drug Abuse, SUBSTANCE ABUSE & MENTAL HEALTH
SERVS. ADMIN., available at http://www.samhsa.gov/rxsafety (last updated Sept. 11, 2009).
9. Twenty-two states have statutes and regulations that address prescriber educa-
tion, and about 73% of those states require education. TRUST FOR AMERICA’S HEALTH,
PRESCRIPTION DRUG ABUSE: STRATEGIES TO STOP THE EPIDEMIC (Oct. 2013), available at
http://tfah.org/reports/drugabuse2013/ [hereinafter STRATEGIES TO STOP THE
EPIDEMIC].
10. States such as Florida, Kentucky, and Utah have seen a reduction in prescrip-
tion drug-related overdose deaths. In 2013, Maine pharmacy robberies fell by nearly 80
percent. Moreover, prescription drug abuse has declined among adults ages 18 to 25.
Press Release, Fla. Dep’t of Law Enforcement, Prescription Drug Deaths Falling Across
Florida (Sept. 24, 2013), http://www.fdle.state.fl.us/Content/News /2013/September/
Prescription-drug-deaths-falling-across-Florida.aspx; Kentucky Sees Slight Decline in Drug
Overdose Deaths, Including Prescription drug Overdose, NAT’L ASS’N OF BDS. OF PHARMACY
(Aug. 7, 2013), http://www.nabp.net/news/kentucky-sees-slight-decline-in-drug-over-
dose-deaths-including-prescription-drug-overdose; UTAH PHARM. DRUG CRIME PROJECT,
UTAH PHARMACEUTICAL DRUG ABUSE BRIEF (Feb. 2012), http://www.useonlyasdirected
.org/wp-content/uploads/2014/07/upd.pdf; Maine Pharmacy Robberies Fall Nearly 80 Per-
cent, WCSH6, June 10, 2013, available at http://host-38.242.54.159.gannett.com/news/
article/246527/2/Maine-pharmacy-robberies-fall-nearly-80-percent; Donna Leinwand
Leger, Prescription Drug Abuse Drops Among Young People, USA TODAY (Sept. 25,
2012), available at http://usatoday30.usatoday.com/news/nation/story/2012-09-25/pre-
scription-drug-use/57838922/1.
11. CENT. FOR LAWFUL ACCESS & ABUSE DETERRENCE, NATIONAL PRESCRIPTION DRUG
ABUSE PREVENTION STRATEGY 2011-2012 UPDATE 16 (2012), http://claad.org/wp-content/
uploads/2013/10/CLAAD_Strategy2011_v3.pdf [hereinafter NATIONAL STRATEGY
UPDATE].
12. Biologics are pharmaceutical products made with viruses, therapeutic serums,
toxins, antitoxins, vaccines, blood, blood components or derivatives, allergenic products,
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growing at twice the rate of the market for chemical drugs.13  Biologics
have been responsible for breakthroughs in treating cancer, multiple
sclerosis, rheumatoid arthritis, HIV/AIDS, and many other illnesses and
conditions.14
Biologics are highly sensitive medications that require strict tem-
perature and storage controls, the lack of which could make them inef-
fective.  They must be transported, stored, and handled with care from
the point of manufacture until the point of patient administration.15
And yet, much like opioids, biologics are also commonly diverted from
their intended destination and uses, which means these drugs risk
being compromised before the patient receives them.  For instance,
state investigators in Florida found a biologic used to treat cancer in an
unimaginable place: an oversized cooler in the back room of a strip
club.16  Although the medication strayed from the closed system of
pharmaceutical distribution, undoubtedly, this medication was still
intended for resale.
Similarly, between 2004 and 2008 alone, 31 health care practition-
ers were arrested for knowingly injecting an unapproved substitute of
the biologic, botulinum toxin type A—a pharmaceutical approved to
treat patients with certain neuromuscular conditions and chronic
migraines and also used cosmetically to reduce wrinkles—into nearly
1,000 unknowing patients.  The botulinum biologic was purchased
from illicit sources and caused paralysis in a least four people.17  Most
of the health care professionals involved misrepresented the product to
their patients, causing them to believe they were receiving the US Food
and Drug Administration (“FDA”)-approved botulinum toxin type A.18
In 2012, the FDA found that a total of 76 physicians in 22 states
had purchased cancer-treating biologics from unapproved sources
protein, or analogous products that are applicable to the prevention, treatment, or cure
of a disease or condition of human beings.  42 U.S.C. § 262(i) (2012).
13. Tanaz Petigara & Gerard Anderson, Strategies to Reduce the High Cost of Biologics,
HEALTH POL’Y MONITOR (2008), http://www.hpm.org/us/b12/3.pdf.  For instance, the
FDA’s Center for Drug Evaluation and Research approved 39 new molecular entities in
2012—the largest number in 15 years. See New Molecular Entity Approvals for 2012, FDA,
www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation /ucm336115.htm
(last visited Aug. 10, 2013).
14. NAT’L PHYSICIANS BIOLOGICS WORKING GROUP, ALLIANCE FOR PATIENT ACCESS,
BIOLOGICS: A DIFFERENT CLASS OF MEDICATIONS THAT MAKE A DIFFERENCE FOR OUR
PATIENTS 2 (2011), http://allianceforpatientaccess.org/120117%20NPBWGWhitePaper
.pdf [hereinafter ALLIANCE FOR PATIENT ACCESS]
15. See What Are “Biologics” Questions and Answers, FDA, http://www.fda.gov/
AboutFDA /CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077
.htm (last visited Feb. 27, 2014).
16. Thomas T. Kubic, Beer Cooler Biologics: The Dangers of Counterfeit Drugs, THE
POLICE CHIEF, http://www.policechiefmagazine.org/magazine/index.cfm?fuseaction=dis
play_arch&article_id=1575&issue_id=82008 (last visited Feb. 27, 2014).
17. FDA Law Enforcers Crack Down on Illegal Botox Scammers, U.S. FOOD & DRUG
ADMIN. (Oct. 2009), http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/
UCM143721.pdf [hereinafter FDA Law Enforcers Crack Down]; Antigone Barton et al., Some
Suspect Faux Botox Paralyzed 4 Patients, THE PALM BEACH POST, Dec. 1, 2004, at 1A.
18. Id.
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throughout an illicit distribution chain.19  According to one oncologist,
patients who received the illegally obtained cancer medication instead
of the legitimate medication “could have lost several months of their
lives.”20
Unfortunately, improper channels of distribution are not uncom-
mon due to the sophistication of the gray market for pharmaceuticals,
and for biologics in particular.  In contrast to the black market, which
deals in medications that start off as counterfeit, the gray market sup-
plies legitimate, legally compliant goods that are made by licensed man-
ufacturers but are distributed by unauthorized dealers or to
unauthorized purchasers.21  The gray market involves “diversion” of
prescription drugs, which is “defined as the transfer of a prescription
medication from a lawful to an unlawful channel of distribution or
use.”22  Drugs may be diverted to unauthorized distributors or corrupt
physicians23 operating “pill mills”24 or to individuals seeking drugs to
sell or abuse.25  In fact, those who traffic controlled substances, such as
opioids, often traffic biologics as well in order to increase profits at
patients’ expense.26
19. Christopher Weaver & Jeanne Whalen, How Fake Cancer Drugs Entered U.S., Wall
St. J. (July 20, 2012, 3:02 PM), http://online.wsj.com/news/articles/SB100014240527
02303879604577410430607090226.
20. Id.
21. William Richardson, Limiting Counterfeit Goods and Parallel Imports: An Effective
Approach, 2 IN-HOUSE PERSP. 5, 6 (2006).
22. NATIONAL STRATEGY UPDATE, supra note 11. R
23. As used in this article, the term “physician” includes all licensed prescribers.
24. “A ‘pill mill’ is a [physician’s] office, clinic, or health care facility that routinely
colludes in the prescribing and dispensing of controlled substances outside the scope of
the prevailing standards of medical practice in the community or violates [state or federal
laws] regarding the prescribing or dispensing of controlled prescription drugs.” Office of
Drug Control’s Definition of a “Pill Mill,” FLA. PDMP FOUND., INC., http://www.flpdmpfoun
dation.com/documents/Office%20of%20Drug%20Control%20Definition%20of%20a%
20Pill%20Mill.pdf.
25. United States v. Cabrera, 284 F. App’x. 674, 685 (11th Cir. 2008); United States
v. Costanzo, 4 F.3d 658, 660 (8th Cir. 1993).  In 2012, a survey showed that most of the
opioids used by individuals for nonmedical purposes (80.3%) were diverted from the
originally intended recipient.
Among persons aged 12 or older in 2011-2012 who used pain relievers nonmedically
in the past year, 54.0 percent got the pain relievers they most recently used from a friend
or relative for free . . . . Another 10.9 percent bought them from a friend or relative.  In
addition, 4.0 percent of these nonmedical users in 2011-2012 took pain relievers from a
friend or relative without asking. An annual average of 4.3 percent got pain relievers from
a drug dealer or other stranger; 1.8 percent got pain relievers from more than one doc-
tor; 0.8 percent stole pain relievers from a doctor’s office, clinic, hospital, or pharmacy
(which was higher than the 0.2 percent in 2009-2010); and 0.2 percent bought the pain
relievers on the Internet.
Only one in five (19.7 percent) received the medications through a prescription
from one doctor. See SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., RESULTS FROM
THE 2012 NATIONAL SURVEY ON DRUG USE AND HEALTH: SUMMARY OF NATIONAL FINDINGS
Ch. 2 (2013), http://store.samhsa.gov/product/Results-from-the-2012-National-Survey-
on-Drug-Use-and-Health-NSDUH-H-47-Mental-Health-Findings/SMA13-4805 [hereinafter
2012 SURVEY].
26. See Press Release, U.S. Attorney’s Office, Eastern District of Missouri, Local Doc-
tor Pleads Guilty to Making False Statement to Agent (Nov. 6, 2013), http://www.justice
.gov/usao/moe/news/2013/november /falconer_erick.html.
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Quality is uncertain for gray market products that leave the legiti-
mate supply chain.27  Gray market medications may be expired, diluted,
contaminated, tainted due to improper storage conditions, or relabeled
with the wrong information.28  And yet, much like the public’s mis-
perception that controlled substances are inherently less risky than
illicit substances, most health care professionals are misinformed about
the safety of gray market biologics.  One key distinction between the
illicit markets for controlled substances and biologics is that the end
users of biologics are typically unwitting participants in the gray market,
and, therefore, are unaware of the risks to their health.29
The regulation of pharmaceuticals, including biologics, is frac-
tioned.  State law governs distribution, repackaging, dispensing, and
returns of pharmaceuticals, often without coordination between
states.30  “Drug approval and manufacturing is governed by federal law,
often with limited coordination with state activities and underfunding
for enforcement,”31 leading the FDA to prosecute only the most egre-
gious cases.
Gray market activity exists throughout the entire system of distribu-
tion, and involves brokers, wholesalers, importers, repackagers, sales
representatives, physicians, and pharmacists.  However, health care
practitioners and pharmacists are the gatekeepers of both controlled
substances and biologics—the last link in the chain of distribution
before the medication reaches the patient.  They have an obligation to
ensure patients are dispensed or administered legitimate medications
that are distributed through closed systems designed to ensure patient
safety.  In doing so, they also protect themselves from civil and criminal
liability.  Yet, according to a recent survey of purchasing agents and
pharmacists at 549 hospitals, 52 percent of all respondents reported
purchasing one or more pharmaceutical products from gray market
vendors over a two year period,32 many mistakenly believing that such
activity is legal.
27. FDA Conducts Preliminary Review of Agency’s Diversion and Counterfeit Criminal Case
Information, U.S. FOOD & DRUG ADMIN., Sept. 2011, http://www.fda.gov/downloads/
Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/UCM272150.pdf [hereinafter
FDA Conducts Preliminary Review].
28. Id.
29. Prescription Drug Abuse, OFFICE OF NAT’L DRUG CONTROL POLICY, http://www
.whitehouse.gov/ondcp/prescription-drug-abuse (last visited Aug. 14, 2012) (“Some indi-
viduals who [abuse] prescription drugs, particularly teens, believe these substances are
safer than illicit drugs because they are prescribed by a healthcare professional and dis-
pensed by a pharmacist.”).
30. Bryan A. Liang, Fade to Black: Importation and Counterfeit Drugs, 32 AM. J.L. &
MED. 279, 288 (2006).
31. Id. See NAT’L ASS’N OF BDS. OF PHARMACY, WHOLESALE DRUG DISTRIBUTION: PRO-
TECTING THE INTEGRITY OF THE NATION’S PRESCRIPTION DRUG SUPPLY 1, 8–9 (AUG. 2013),
http://www.nabp.net/system/rich/rich_files/rich_files/000/000/064/original/whole-
sale-drug-distribution-protecting-the-integrity-of-the-nations-prescription-drug-supply.pdf.
32. Gray Market, Black Heart: Pharmaceutical Gray Market Finds a Disturbing Niche Dur-
ing the Drug Shortage Crisis, INST. FOR SAFE MEDICATION PRACTICES (Aug. 25, 2011), http://
www.ismp.org/newsletters/acutecare/showarticle.asp?ID=3 [hereinafter Gray Market,
Black Heart].
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When regulating the dispensing, administering, and reselling of
biologics, much like regulating opioids, states are in the best position to
deal with potential drug-related health and safety threats, as exempli-
fied by statutes and regulations promulgated to prevent diversion and
overprescribing of controlled substances and enforcement thereof.33
In order to ensure pharmacists and health care practitioners, first,
understand legal requirements and harmful repercussions for dispens-
ing and administering gray market biologics and, second, are punished
severely enough to deter others from participation in such activities,
state lawmakers should look to the education and enforcement systems
used in the opioid abuse epidemic as a framework within which to
direct their actions.  This includes requiring proper prescriber and
pharmacist education, investigating suspicious activity, referring inten-
tional wrongdoing to prosecutors, and directing cases of negligence or
ignorance to licensing boards.  Health care institutes and professionals
must ensure compliance by following best practices in risk manage-
ment. Increasing consumer awareness is also an essential component of
reducing the threats associated with gray market biologics.
This Article examines the gray market for biologics, provides a
comprehensive analysis of the various federal and state criminal laws
that health care practitioners and pharmacists may violate,34 identifies
problems with the current legal landscape, and proposes solutions that
can be incorporated into the education and enforcement systems used
to curb the prescription drug abuse epidemic.  This Article may be used
as a resource for physicians, pharmacists, and their legal counsel to edu-
cate themselves on the criminal liability health care providers may face.
It may serve as a valuable source for state policymakers to use in assess-
ing laws and regulations.  It may also be useful to prosecutors and law
enforcement in investigations.
Part I of this article provides a summary of the prescription drug
abuse epidemic, the nature of biologics, and why the gray market for
biologics exists.  Part II provides an analysis of the most common crimi-
nal causes of action brought under federal and state law when physi-
cians and pharmacists divert pharmaceuticals to the gray market.
Finally, based on the prescription drug abuse model, Part III will sug-
gest steps that can be taken to hold gray market participants accounta-
ble and improve the safety and welfare of patients who may otherwise
unknowingly be dispensed or administered harmful or ineffective
diverted biologic medications.35
33. Jason Kane, Drug Prices Soar as Hospital Suppliers Are Forced into ‘Gray Market’, PBS
NEWSHOUR (Aug. 29, 2011, 5:18 PM), http://www.pbs.org/newshour/rundown/2011/
08/drug-prices-soar-as-pharmacists-are-forced-into-gray-market.html (noting that the
FDA’s Office of Criminal Investigations looks into complaints about blatant safety con-
cerns in the gray market but the agency defers to the states to do the bulk of regulation).
34. Although manufacturers and distributors may also be bad actors within the gray
market distribution chain, this article does not focus on them.
35. See infra Part III.
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II. OVERVIEW OF OPIOID ABUSE AND THE GRAY
MARKET FOR BIOLOGICS
This section describes the prescription drug abuse epidemic and
biologics, and provides an overview of biologics.  It explains how the
gray market for biologics operates, including the various ways in which
biologics commonly travel through illicit channels and reasons for the
existence of the gray market for biologics.
A. The Prescription Opioid Epidemic
Opioids can be useful in treating both pain and addiction when
used as prescribed.36  When opioids and other medications are used in
ways that are not as prescribed, abuse occurs.37  Recent data indicates
that over 1.9 million people begin abusing opioids every year.38  Public
perception sees prescription medications as inherently safer than illicit
substances,39 and yet, in 2009, nearly 4.6 million emergency room visits
were drug related, approximately 2.1 million of which involved misuse
or abuse of pharmaceuticals.40  In 2010, 16,651 overdose deaths
involved opioid medications.41  Opioid “diversion occurs at every point
in the drug supply chain,” including at the distribution and retail levels
through theft, illicit online pharmacies, and pill mills.42  Some drug
abusers acquire prescription medications through illicit channels, while
others obtain prescriptions directly from prescribers.43  Although at the
fringe, some physicians operate pill mills, acting as little more than
drug dealers.44  The rapid increase in opioid deaths directly correlates
to the increase in opioid pain medication sales, and it is clear that the
36. NAT’L SAFETY COUNCIL, PRESCRIPTION NATION: ADDRESSING AMERICA’S PRESCRIP-
TION DRUG ABUSE EPIDEMIC (2013), http://www.nsc.org/safety_home/PrescriptionDrug
Overdoses/Documents/Prescription%20Nation%20Report.pdf [hereinafter PRESCRIP-
TION NATION].
37. Misuse is distinguishable from abuse.  Abuse, as defined above, is “the inten-
tional self-administration of a medication for a nonmedical purpose such as ‘getting
high.’”  In contrast, misuse is “the use of medication for a medical purpose other than as
directed or indicated, whether willful or unintentional, and whether harm results or not.
Misusing medications includes behaviors such as self-medicating without a prescription,
using the medication for another indication than that for which it was prescribed, and
increasing the dose of a prescribed medication.”  In this Article, “abuse” includes “mis-
use.” See also NATIONAL STRATEGY, supra note 2. R
38. 2012 SURVEY, supra note 25. R
39. Prescription Drug Abuse, supra note 29 (“Some individuals who [abuse] prescrip- R
tion drugs, particularly teens, believe these substances are safer than illicit drugs because
they are prescribed by a healthcare professional and dispensed by a pharmacist.”).
40. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., THE DAWN REPORT: HIGH-
LIGHTS OF THE 2009 DRUG ABUSE WARNING NETWORK (DAWN) FINDINGS ON DRUG-RELATED
EMERGENCY DEPARTMENT VISITS (2010), http://www.oas.samhsa.gov/2k10/DAWN034/ED
Highlights.htm.
41. Press Release, U.S. CTRS. FOR DISEASE CONTROL & PREVENTION, supra note 1. R
42. Laura A. Stokowski, Drug Diversion in the United States, MEDSCAPE NEUROLOGY,
Mar. 31, 2008, http://www.medscape.org/viewarticle/572103.
43. Michael C. Barnes & Stacey L. Sklaver, Active Verification and Vigilance: A Method
to Avoid Civil and Criminal Liability When Prescribing Controlled Substances, 15 DEPAUL J.
HEALTH CARE L. 93, 95 (2013).
44. Id.
\\jciprod01\productn\N\NDE\29-2\NDE203.txt unknown Seq: 8 20-APR-15 16:47
382 NOTRE DAME JOURNAL OF LAW, ETHICS & PUBLIC POLICY [Vol. 29
increase in the availability of opioids parallels an increase in addiction
and overdose deaths.45
To prevent diversion and resultant overdose deaths, the federal
Controlled Substances Act (“CSA”) was promulgated in 1970,46 and
states have promulgated their own state controlled substances acts.47
Authority to regulate the flow of medicine through interstate com-
merce falls under the federal purview while the authority to regulate
intrastate commerce and the practice of medicine falls under state pur-
view.48  The CSA imposes duties on the entities along the closed system
of controlled substance distribution related to the products’ manufac-
ture, labeling and packaging, transportation, prescribing, sale, and dis-
posal, and allows the US Drug Enforcement Administration (“DEA”)
and state law enforcement to investigate and criminally prosecute those
who improperly prescribe.49  At the same time, states have broad
authority under their police powers to regulate professional practice,
and have traditionally regulated both the practices of medicine and
pharmacy.50  While differences between state laws and regulations may
contribute to the national epidemic,51 state leadership and action have
also resulted in signs of improvement over the past few years.52  In fact,
a government report showed that prescription drug abuse decreased in
ten states from 2010 to 2011 and did not increase in any state that
year.53  Strategies employed to reduce prescription opioid diversion
may also be used to reduce diversion of biologics, as described herein.
B. Overview of Biologics
Biologics are made up of large, complex cells and living organisms,
in contrast to traditional, small molecule chemical drugs, which have
45. PRESCRIPTION NATION, supra note 36, at 5. R
46. 21 U.S.C. §§ 801–971 (2011).
47. Barnes & Sklaver, supra note 43 at 96. R
48. Michael C. Barnes & Gretchen Arndt, The Best of Both Worlds: Applying Federal
Commerce and State Policy Powers to Reduce Prescription Drug Abuse, 16 J. HEALTH CARE L. &
POL’Y 271, 280 (2013).
49. 21 C.F.R. § 1301.71(a); Practitioner’s Manual, An Informational Outline of the Con-
trolled Substances Act, U.S. DRUG ENFORCEMENT ADMIN., OFFICE OF DIVERSION CONTROL
(2006) http://www.deadiversion.usdoj.gov/pubs/manuals/pract/index.html (last visited
Feb. 17, 2014).
50. See, e.g., Barnes & Arndt, supra note 48, at 273 (noting that both the federal R
government and the states regulate prescription drugs concurrently). For example,
courts have recognized that federal law does not restrict the ability of a physician to pre-
scribe a legal drug for any purpose, regardless of whether the FDA has approved the drug
for that specific use. See Wash. Legal Found. v. Henney, 202 F.3d 331, 333 (D.C. Cir.
2000) (approving of “off-label” prescriptions).
51. PRESCRIPTION NATION, supra note 36. R
52. Prescription Drug Abuse Decreasing in Some States, DRUGFREE.ORG (Jan. 9, 2013),
http://www.drugfree.org/join-together/prescription-drugs/prescription-drug-abuse-
decreasing-in-some-states.
53. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., THE NATIONAL SURVEY ON
DRUG USE & HEALTH REPORT: STATE ESTIMATES OF NONMEDICAL USE OF PRESCRIPTION PAIN
RELIEVERS (2013), http://www.samhsa.gov/data/2k12/NSDUH115/sr115-nonmedical-
use-pain-relievers.htm.
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well-defined chemical structures.54  Biologics are manufactured using a
complex process,55 making it almost impossible to reproduce identical
copies.56  The process of creating biologics is important to the medica-
tion’s efficacy, and therefore, any minor change to the manufacturing
process can significantly alter the biologic and its effectiveness in the
body.57  After biologics leave the manufacturer, they must remain in
their approved containers, be maintained according to precise han-
dling processes, be stored within a specific temperature range, and be
used before the expiration date.58  Otherwise, the drug product may
lose efficacy or potency, “which can lead to interruptions in treatment
protocol, adverse events, or failure to relieve patient symptoms.”59
Such problems not only impact the individual’s health but can become
a widespread public health issue, particularly when vaccines are
involved.60
C. Overview of The Gray Market
In the proper closed system of distribution, biologics manufactur-
ers typically sell their products to wholesale distributors, and wholesale
distributors then sell to pharmacies, hospitals, or authorized practition-
ers pursuant to the Food, Drug and Cosmetics Act (“FDCA”).61  The
54. How do Drugs and Biologics Differ?, BIOTECHNOLOGY INDUS. ORG. (Nov. 10, 2010),
http://www.bio.org/articles/how-do-drugs-and-biologics-differ; ALLIANCE FOR PATIENT
ACCESS, supra note 14. Biologics may be composed of sugars, proteins, nucleic acids, or R
other living entities, although many of the most commonly used biologics are proteins.
What Are “Biologics” Questions and Answers, supra note 15; AM. SOC’Y FOR CANCER ACTION R
NETWORK, UNDERSTANDING BIOLOGIC MEDICINES FROM THE CANCER PATIENT PERSPECTIVE
17 (2013) [hereinafter UNDERSTANDING BIOLOGIC MEDICINES].
55. Often times, the process invokes a recombinant technique, which involves the
“insertion of select genes into cell lines grown in cultures to manufacture molecules with
specific qualities.” Once the molecules are isolated, they are used as the active ingredients
in the biological drug. UNDERSTANDING BIOLOGIC MEDICINES, supra note 54, at 6–7. R
56. Bryan A. Liang, Regulating Follow-On Biologics, 44 HARV. J. ON LEGIS. 363, 369–70
(2007) (noting that whereas biologics are composed of “thousands to millions of atoms
[that] form[ ] . . . an interconnected group of hundreds [and even] thousands of amino
acids aggregated into chains and subgroups,” chemical drugs usually consist of only doz-
ens of atoms that form a single molecule). See also Press Release, U.S. FOOD & DRUG
ADMIN., U.S. FDA Considerations: Discussion by National Regulatory Authorities with
World Health Organization (WHO) on Possible International Non-proprietary Name
(INN) Policies for Biosimilars (Sept. 1, 2006), http://www.fda.gov/Drugs/Development
ApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/Thera
peuticBiologicApplications/Biosimilars/ucm375086.htm (finding that biologics from dif-
ferent manufacturers may not be interchangeable because “[d]ifferent large protein
products, with similar molecular composition may behave differently in people and sub-
stitution of one for another may result in serious health outcomes .  . .”).
57. How do Drugs and Biologics Differ?, supra note 54. R
58. Majority of Physicians Concerned about Risks to Patients from Heat Damaged Products,
BUSINESS WIRE (June 22, 2010), http://www.businesswire.com/news/home/20100622005
537/en/Majority-Physicians-Concerned-Risks-Patients-Heat-Damaged#.Uw9XwvldW4J.
59. Id.
60. Id.
61. See 21 U.S.C. § 353(e)(3)(B) (2012) (defining the term wholesale distribution).
Approximately 90% of pharmaceutical sales involve direct transactions from large whole-
sale distributors to pharmacies or practitioners.  Liang, supra note 30, at 287.  It should be
noted that smaller hospitals or pharmacies tend to use secondary distributors because
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pharmacy, hospital, or practitioner will then dispense or administer the
biologic to the patient.  In some cases, the manufacturer delivers the
biologic directly to licensed health care professionals without using a
distributor.62  The limited number of transactions in the traditional
supply chain ensures that biologics pass through as few hands as possi-
ble in order to maintain the products’ safety and integrity.
In contrast, biologics in a gray market chain deviate from the
closed system of distribution and enter a longer process, in which they
are often sold multiple times between middlemen before they are ulti-
mately dispensed to a patient.63  The complexity of this drug supply
chain presents an array of opportunities for the drugs to be contami-
nated, expire, spoil, or lose their efficacy.64  Moreover, the gray market
creates greater opportunity for counterfeit biologics to enter the mar-
ketplace.65  Given that the same dishonest parties who operate on the
gray market also operate on the black market, counterfeit medications
and legitimate gray market medications are often combined and sold
together in the same lot.
There is no certainty that a biologic from the gray market is safe or
is what it is purported to be, especially because biologics are particularly
easy to mimic or dilute.66  Many injectable biologics come in the form
of clear fluids in traditional vials.67  A counterfeit biologic can be a
diluted version of the drug or even mere saline with no active ingredi-
ent.68  In some cases, active ingredients have been replaced with poten-
tially harmful ones, including powdered cement, toxic yellow road
paint, floor wax, boric acid, or antifreeze, in hopes of making counter-
feit chemical drugs appear more realistic.69  Yet, unlike buying an imita-
tion Rolex watch at a street kiosk, consumers who purchase
pharmaceutical drugs rarely have any indication that their medications
they lack the purchasing power to buy directly from major distributors. Kane, supra note
33.
62. See Allergan’s Botox – Botulinum Toxin Type A – Not the Cause of Botulism in Florida
Patients, BUSINESS WIRE (Dec. 13, 2004, 9:01 AM), http://www.businesswire.com/news/
home/20041213005370/en/Allergans-BOTOX——Botulinum-Toxin-Type—-#.VEGrefnF
9dM (stating that “Allergan only ships BOTOX(R) and BOTOX(R) Cosmetic on dry ice
directly to the licensed health care professional . . .”).
63. Id.
64. Securing Our Nation’s Prescription Drug Supply Chain: Hearing Before the House Sub-
comm. on Health of the H. Comm. on Energy and Commerce, 113th Cong. 12 (2013) (statement
of Janet Woodcock, Director, Center for Drug Evaluation and Research, U.S. Food and
Drug Administration).
65. Liang, supra note 30, at 287.
66. See, e.g., Wyatt Yankus, Counterfeit Drugs: Coming to a Pharmacy Near You, THE AM.
COUNCIL ON SCI. & HEALTH 8 (Aug. 2006), http://www.acsh.org/wp-content/uploads/
2012/04/200608171_counterfeitdrugw.pdf (discussing the FDA’s inability to verify the
safety of re-imported drugs because they lie outside of the regulated supply chain);
Internet Drug Outlet Identification Program Updated Progress Report: April 2012 – Re-issued May
14, 2012, NAT’L ASS’N OF BDS. OF PHARMACY 6 (May 14, 2012), http://www.nabp.net/
news/assets/IDOIReportApril11.pdf; Liang, supra note 56, at 379.
67. Liang, supra note 56, at 379.
68. Bad Medicine, 25 NATURE BIOTECHNOLOGY 707, 708 (2007); see Liang, supra note
56, at 379 (discussing opportunities for diversion).
69. Liang, supra note 30, at 284.
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are imitations because such drugs are dispensed in legitimate pharma-
cies and medical settings.
When the stability of active ingredients in a biologic is threatened,
the patient taking such a drug may incur an adverse immune
response.70  However, rather than worry about harm to the end con-
sumer, participants in the gray market are typically more focused on
profits.71  On average, gray market medications cost 650% more than
the initial price by the time the medication reaches the end user.72  Bad
actors exploit shortages for complex, life-saving biologics, such as those
used for oncology, cardiology, and critical care, by hoarding such medi-
cations and selling them on the gray market.73  Purchasing agents are
then placed in difficult ethical situations where they must choose
between going without vital medications or purchasing medications at
high prices with no guarantee of their safety and efficacy.74  Another
reason that the gray market for biologics exists is the high costs of such
pharmaceuticals that can stem from complex manufacturing
70. In a phenomenon known as immunogenicity, the immune system may begin to
create its own anti-bodies that fight off the biologic that it deems as foreign, similarly to
how it fights a virus like the flu.  This response is typically absent in traditional, chemical
drugs because their small molecule size typically goes undetected by the immune system.
As a result of the “foreign” biologic, subsequent administrations of the drug become inef-
fective and in severe instances cause anaphylactic shock and death.  The timing of the
immune response may vary and multiple administrations of the biologic may occur prior
to the presence of physical evidence, making it difficult to establish whether the reaction
is due to the biologic, human variation, or the progression of the individual’s disease.
UNDERSTANDING BIOLOGIC MEDICINES, supra note 54, at 15.
71. KATHERINE EBAN, DANGEROUS DOSES: HOW COUNTERFEITERS ARE CONTAMINATING
AMERICA’S DRUG SUPPLY 2 (2005); see also PEW HEALTH GROUP, AFTER HEPARIN: PROTECT-
ING CONSUMERS FROM THE RISKS OF SUBSTANDARD AND COUNTERFEIT DRUGS, 15 (Jul. 12,
2011), http://www.pewtrusts.org/en/research-and-analysis/reports/2011/07/12/after-
heparin-protecting-consumers-from-the-risks-of-substandard-and-counterfeit-drugs (not-
ing that “the return on counterfeit prescription drugs may be 10 times greater than that
of the sale of illegal narcotics”).
72. SEN. COMM. ON COMMERCE, SCIENCE, & TRANSPOR., SHINING LIGHT ON THE “GRAY
MARKET” AN EXAMINATION OF WHY HOSPITALS ARE FORCED TO PAY EXORBITANT PRICES FOR
PRESCRIPTION DRUGS FACING CRITICAL SHORTAGES 5 (July 25, 2012) [hereinafter SHINING
LIGHT ON THE “GRAY MARKET”].
73. Mitigating Risks To The Supply Chain After A Drug Shortage Occurs, RX-360 SUPPLY
CHAIN SECURITY DRUG SHORTAGE WORKING GROUP 3 (May 3, 2013), http://www.rx-360
.org/LinkClick.aspx?fileticket=wHdILXf0DXA%3d&tabid=246; Justin Schuster, America’s
Drug Problem, THE POLITIC: THE YALE UNDERGRADUATE J. (Feb. 11, 2013).  Causes of
shortages include increased demand, corporate delays in manufacturing or shipping,
quality issues that mandate a recall or stop in production, distribution disruptions, pro-
duction changes, unavailability of component materials, new indications, decisions to dis-
continue the product, or natural disasters. CBER-Regulated Products: Possible Causes of
Shortage, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/BiologicsBloodVaccines/Safety-
Availability/Shortages/ucm351909.htm (last updated Aug. 9, 2013).
74. See Gray Market, Black Heart, supra note 32 (noting that many prescription drug
purchasers feel pressured by physicians and hospital administrators to purchase gray mar-
ket drugs, despite costs and safety concerns).  Biologics that are essential to treating criti-
cally ill patients are often marked up even higher than other types of pharmaceuticals in
the gray market.  Extreme examples include a 4,533% mark-up on the cardiology drug
Labetalol and a 3,980% mark-up on the oncology drug Cytarabine.  COLEEN CHERICI ET
AL., BUYER BEWARE: DRUG SHORTAGES AND THE GRAY MARKET 2 (2011), http://www
.chcablog.com/wp-content/uploads/2011/08/Gray-Market-Analysis-David-Edit.pdf.
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processes75 and extensive research and development.76  In fact, bio-
logics may cost up to twenty two times more than traditional chemical
drugs.77
Some entities throughout the system of distribution lack the knowl-
edge to realize that their actions are illegal or could result in danger to
the patients.  They may act with altruistic intentions, such as trying to
save patients money or obtain life-saving medications in short supply.
Others participate in willful wrongdoing.  These criminals exploit igno-
rance about the law and harmful effects of gray market biologics, fur-
thering their unlawful aim.  Furthermore, as is the case with opioids,
criminals use many methods to obtain legitimate biologics and divert
them to illicit uses.  This section discusses some of those methods.
1. Resale of Biologics Intended for Nonprofits and Foreign Markets
Pursuant to the Robinson-Patman Act, both biologic and chemical
pharmaceutical manufacturers may maintain a bifurcated pricing struc-
ture.78  Manufacturers may offer a standard market price to wholesale
distributors who resell the drugs to the majority of buyers in the United
States.79  They may also offer a second, deeply discounted price to dis-
tributors who resell to nonprofit organizations, such as charitable hospi-
tals and pharmacies, and to US exporters who obtain drugs
manufactured in the United States and resell them abroad.80  Drugs
intended for foreign markets may be sold at lower rates than their US
market versions, especially those foreign markets subject to govern-
ment-imposed price controls.
To comply with the Robinson-Patman Act, nonprofits may only buy
deeply discounted drugs if such drugs are exclusively for the nonprof-
its’ internal use.81  Similarly, US exporters may only accept the dis-
counted rate if they export the drug out of the United States to sell to
75. See Jeanne Yang, A Pathway to Follow-On Biologics, 3 HASTINGS SCI. & TECH. L.J.
217, 223 (2011) (noting that compared with chemical medications, which require forty to
fifty laboratory tests during manufacturing, scientists creating biologics must undertake
250 or more tests).
76. See PHARM. RESEARCHERS & MFRS. OF AM., 2013 PROFILE BIOPHARMACEUTICAL
RESEARCH INDUSTRY PROFILE 32 (July 2013), http://www.phrma.org/sites/default/files/
pdf/PhRMA%20Profile% 202013.pdf (confirming that the average cost of creating a new
biologic is $1.2 billion and typically takes ten to fifteen years from the initial discovery).
77. See Hilary Kramer, Why Biologics Remain Expensive, FORBES (Dec. 4, 2009), http://
www.forbes.com/2009/12/03/kramer-health-care-intelligent-investing-pharmaceuticals
.html (noting the lack of generic alternatives to biologics as one of the reasons for its high
cost for consumers).  For example, the chemical drug to treat rheumatoid arthritis costs
approximately $300 per year, but the biologic, which treats the same condition, costs
approximately $26,000 per year.  Julie D. Polovina, Mutant Biologics: The 2010 Health-
Reform Legislation’s Potential Impact on Reducing Biologic Research and Development Costs, 100
GEO. L.J. 2291, 2296 (2012).
78. Robinson-Patman Act, 15 U.S.C. §§ 13–13(c) (2012); United States v. Wein-
stein, 762 F.2d 1522, 1527 (11th Cir. 1985).
79. Weinstein, 762 F.2d at 1527.
80. Id.
81. 15 U.S.C. § 13c (2012).
\\jciprod01\productn\N\NDE\29-2\NDE203.txt unknown Seq: 13 20-APR-15 16:47
2015] APPLYING LESSONS FROM THE OPIOID ABUSE EPIDEMIC 387
the intended country abroad.82  Such drugs may not be reimported
back into the United States for domestic sale.83  The same is true for
distributors who purchase drugs intended for foreign markets from
manufacturers located abroad.84
Yet, incentivized by the prospect of profit and sometimes under the
guise of greater fairness by lowering costs to consumers, gray market
distributors often seek to purchase biologics in short supply back from
willing nonprofit organizations, exporters, and foreign distributors at
discounted rates to then resell them in the US market at a higher
cost.85  This arrangement allows gray market participants to purchase
prescription drugs at relatively low cost and then divert them to third-
party purchasers to which credible, initial wholesalers may not normally
sell.86
2. Pharmacies
A 2012 congressional report studying 300 drug distribution chains
found that more than two-thirds of gray market pharmaceuticals were
diverted from pharmacies.87  Instead of dispensing the drugs according
to professional duties, state laws, and the expectations of their trading
partners, these pharmacies resold the drugs to gray market wholesal-
ers.88  In fact, some pharmacies sold their entire inventories into the
gray market, operating for the sole purpose of acquiring and selling
short-supply drugs.89
Internet pharmacies are particularly problematic.  A recent study
showed that nearly 97% of online pharmacies are not in compliance
with US pharmacy laws and practice standards,90 and in June 2013, the
FDA took action against 9,600 illegal internet pharmacy websites,
including seizing offending websites and over forty million dollars
worth of illegal medications worldwide.91  Many online pharmacies
obtain both counterfeit and gray market medications from distributors
and resell the drugs below the US market value for legitimate medica-
82. 21 U.S.C. § 381(e) (2012).
83. See infra Part III.
84. See 21 U.S.C. §§ 352–353, 355 (2012).  Any drug that is not approved for use in
the United States by the FDA may not be imported into the United States; therefore,
drugs intended for other countries violate these provisions. See also infra Part II.A.
85. Weinstein, 762 F.2d at 1527; SHINING LIGHT ON THE “GRAY MARKET,” supra note
72, at 18–20.
86. Schuster, supra note 73.  Courts have held that this type of action is fraud.  See
infra Part II.B for further discussion.
87. SHINING LIGHT ON THE “GRAY MARKET,” supra note 72, at 16.
88. Id.
89. Id. at 17.
90. For the Media, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/Resources
ForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/Be
SafeRxKnowYourOnlinePharmacy/ucm294170.htm (last updated Sept. 24, 2013).
91. Press Release,  FDA Takes Action to Protect Consumers from Dangerous
Medicines Sold by Illegal Online Pharmacies (June 27, 2013), http://www.fda.gov/news
events/newsroom/pressannouncements/ucm358794.htm.
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tions emanating from the proper closed system of distribution.92  Many
of the drugs sold on these sites are counterfeit, expired, stolen, diluted,
improperly stored, or impure, or they contain the wrong
concentration.93
3. Samples, Theft, and Buy-Backs
Manufacturers are permitted to distribute sample biologics to
pharmacists and physicians as long as the drugs contain labels stating
that they are not intended for sale.94  However, in some instances, man-
ufacturers or distributors provide samples to pharmacists or physicians,
who will then sell the samples to gray market participants at market
price.95  Additionally, criminal entities sometimes steal biologics from
manufacturers, distributors, or pharmacies and sell them to willing gray
market purchasers.96  Others may purchase medications from consum-
ers who bought the medications for personal use or physicians who
have an extra supply.
4. Practitioners Who “Have No Other Choice”
Practitioners who treat their patients with medications in short sup-
ply are sometimes placed in an ethical conundrum in which they must
choose between having no supply of a drug or purchasing the drug at
an exorbitant price from the gray market.97  According to a recent sur-
vey, forty-two acute care hospitals reported receiving a total of 1,745
gray market solicitations from eighteen recorded gray market vendors
in just two weeks alone, and all of the solicitations involved drugs that
were back-ordered or unavailable through traditional distribution chan-
nels.98  While some hospitals and practitioners maintain policies that
require them to buy drugs only through their regularly trusted net-
works, others have decided to buy drugs from gray market participants
because they feel they have no other choice.99
III. FEDERAL LAW GOVERNING THE GRAY MARKET
Despite a common misperception in the health care industry that
gray market activity is legal, pharmacists and physicians may be prose-
cuted under various federal laws for their participation in the gray mar-
92. See Internet Drug Sales: Hearing Before the H.R. Comm. on Gov’t Reform, 108th Cong.
(Mar. 18, 2004) (statement of William K. Hubbard, Assoc. Comm’r for Policy and Plan-
ning and Legis., FDA).
93. Deceptive Practices by Illegal Online Drug Sellers Give Consumers a False Sense of Legiti-
macy and Safety, Reports NABP, NAT’L ASS’N OF BDS. OF PHARMACY (July 26, 2013), http://
www.nabp.net/news/deceptive-practices-by-illegal-online-drug-sellers-give-consumers-a-
false-sense-of-legitimacy-and-safety-reports-nabp [hereinafter Deceptive Practices].
94. 21 U.S.C. § 353(c)(1) (2012).
95. FDA Conducts Preliminary Review, supra note 27.
96. Schuster, supra note 73.
97. SHINING LIGHT ON THE “GRAY MARKET,” supra note 72, at 5.
98. CHERICI, supra note 74, at 2.
99. Id.
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ket.100  This section discusses some of the criminal causes of action that
may be brought against a gray market participant and also evaluates
their effectiveness.  While some of the cases discussed herein deal with
distributors rather than pharmacists or physicians, and discuss chemical
drugs rather than biologics, the same legal doctrines apply to pharma-
cists and physicians who dispense or administer biologics.
A. Unapproved New and Misbranded Drugs Under the FDCA
Under the FDCA, the FDA regulates the integrity of pharmaceuti-
cals intended for the US market throughout the supply chain, includ-
ing approval, production, distribution, and advertising of prescription
drugs.101  The FDA aims to prevent “unsafe, ineffective, subpotent,
superpotent, or adulterated drugs from reaching pharmacies and
patients in the United States—whether introduced on purpose or inad-
vertently.”102  Virtually all gray market drugs violate the FDCA because
they are either unapproved new drugs or misbranded.103  Biologics may
be classified as “drugs,” based on their mode of action104 and intended
use, and as such, the FDCA drug provisions apply to these biologics.105
1. Unapproved New Drugs
Pursuant to section 355 of the FDCA, “No person shall introduce
or deliver for introduction into interstate commerce any new drug,
unless” the FDA has approved the drug.106  This includes pharmacists
and physicians.107  A “new drug” is defined as follows:
(1) Any drug . . . the composition of which is such that such drug
is not generally recognized, among experts qualified by scientific
training and experience to evaluate the safety and effectiveness of
drugs, as safe and effective for use under the conditions pre-
scribed, recommended, or suggested in the labeling thereof . . . ;
or
(2) Any drug . . . the composition of which is such that such drug,
as a result of investigations to determine its safety and effective-
100. Brokers, manufacturers, wholesalers, importers, repackagers, sales representa-
tives, pharmacists, physicians, other practitioners, consumers, and any other individuals
or entities who participate in gray market activity may be prosecuted under various fed-
eral and state laws; however, this article will focus solely on pharmacists and physicians.
101. SUSAN THAUL, CONG. RESEARCH SERV., R43106, PHARM. SUPPLY CHAIN SEC. 3
(June 12, 2013), available at http://www.rx-360.org/LinkClick.aspx?fileticket=2MO1dO9_
xU0%3D&tabid=355.
102. Id.
103. 21 U.S.C. §§ 352–353, 355 (2012); see 42 U.S.C. § 262(j) (2006).
104. “Mode of Action” is defined as the means by which a product achieves its
intended therapeutic effect or action.  Definition of Primary Mode of Action of a Combi-
nation Product, 70 Fed. Reg. 29848, 49850 (Aug. 25, 2005).
105. United States v. Gallant Pharma Int’l, Inc., Indictment, Criminal No.
1:13CR130, at *2 (E.D. Va. Mar. 27, 2013).
106. 21 U.S.C. §§ 355(a), 331(d) (2012) (emphasis added); United States v. 1500
90-Tablet Bottles, 384 F. Supp. 2d 1205, 1214 (N.D. Ill. 2005).
107. United States v. Evers, 643 F.2d 1043, 1050 (5th Cir. 1981).
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ness for use under such conditions, has become so recognized,
but which has not, otherwise than in such investigations, been
used to a material extent or for a material time under such
conditions.108
Before a new biologic drug may be introduced into interstate com-
merce in the United States, a drug manufacturer must obtain FDA
approval of that drug by submitting a Biologic License Application
(“BLA”) or other relevant application.109  The BLA must contain cer-
tain information, including:
(A) [F]ull reports of investigations which have been made to
show whether or not such drug is safe . . . ;
(B) [A] full list of the articles used as components of such drug;
(C) [A] full statement of the composition of such drug;
(D) [A] full description of the methods used in, and the facilities
and controls used for, the manufacture, processing and packing
of such drug;
(E) [S]amples of such drug . . . ; [and]
(F) [S]pecimens of the labeling proposed to be used for such
drug.110
The FDA also requires BLAs to include detailed information
regarding the specific facilities that manufacture and process the new
drug.111  Upon receipt of a BLA, the FDA reviews the application and
decides whether or not to approve it.112  If a drug deviates from any of
the characteristics in the approved BLA, it is considered an unapproved
new drug and may not be offered for sale in the United States.113  This
is because the FDA does not have the opportunity to review the unap-
proved new drug product before it is marketed to ensure the combina-
tion of ingredients is safe and effective, that the labeling contains
adequate dosing information and appropriate warnings and precau-
tions, and that it was produced, packaged, and handled in safe and
proper conditions.114  The new drug approval process reflects “ ‘a Con-
gressional view that the way in which drugs are mixed and packaged is
108. 21 U.S.C. § 321(p) (2012).
109. 21 U.S.C. § 355 (2012); 42 U.S.C. § 262(a) (2006); United States v. Genendo
Pharm., 485 F.3d 958, 960 (7th Cir. 2007).  Drug manufacturers may also submit a new
drug application (“NDA”) for new small molecule drugs, an abbreviated new drug appli-
cation (“ANDA”) for generic small molecule drugs, or a 505(b)(2) application for generic
small molecule medications or follow-on biologics. Id.; 21 U.S.C. § 355(j) (2012).
110. 21 U.S.C. § 355(b)(1) (2012).
111. 21 C.F.R. § 314.50(d) (2013).
112. 21 U.S.C. § 355(b)(1); United States v. 1500 90-Tablet Bottles, 384 F. Supp. 2d
1205, 1214 (N.D. Ill. 2005).
113. 21 U.S.C. § 321(p)(1); 1500 90-Tablet Bottles, 384 F. Supp. 2d at 1208.
114. Unapproved and Misbranded Oral and Injectable Drugs Labeled for Prescrip-
tion Use Containing Codeine Sulfate, Codeine Phosphate, or Dihydrocodeine Bitartrate,
79 Fed. Reg. 1879 (Jan. 10, 2014) (notice).
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no less important than the chemical makeup of the drugs.’”115  There-
fore, it is not enough that a medication intended for use abroad and
the US-approved version share the same chemical makeup.116  To be
introduced into interstate commerce under the cover of an FDA-
approved BLA, the drugs must comply with all requirements of that
BLA.117
In many cases, biologics that are manufactured and packaged for
sale outside of the United States are not manufactured or packaged in a
facility that is FDA-approved.118  Moreover, even if a manufacturer pro-
duces the FDA-approved biologic and an identical biologic intended for
foreign markets, the version produced for foreign markets usually does
not meet all of the FDA requirements in the approved BLA.119
In United States v. Genendo Pharmaceutical, a pharmaceutical distribu-
tor located in Curacao, Netherlands Antilles, attempted to import into
the United States a version of a prescription drug, atorvastatin, that was
intended for sale in other countries.120  It was undisputed that the
seized atorvastatin had the same chemical composition, as well as other
similarities to FDA-approved atorvastatin.121  However, the FDA-
approved new drug application (“NDA”)122 for atorvastatin required
that the medication: (1) be manufactured at a specific facility in Ire-
land; (2) be packaged at specific facilities in Germany or Puerto Rico;
(3) be packed in 100-tablet boxes containing ten blister cards of ten
tablets each; (4) be labeled in English; and (5) have a two-year expira-
tion period.123  Yet, although the medication was produced by the same
manufacturer in Ireland, it was packaged at a facility in Brazil rather
than an FDA-approved facility in Germany or Puerto Rico.124  Moreo-
ver, it was packaged in boxes containing thirty tablets each and labeled
in Portuguese rather than English.125  Finally, the drug had a three-year
expiration period rather than the approved two-year expiration
period.126
115. 1500 90-Tablet Bottles, 384 F. Supp. 2d at 1215 (quoting United States v. Baxter
Healthcare Corp., 901 F.2d 1401, 1411 (7th Cir. 1990)).
116. Id.
117. Id.
118. Often, even if a manufacturer makes a drug intended for a foreign market that
is identical to the FDA-approved drug intended for the U.S. market, the manufacturer
will still produce and package that drug in a separate facility from the one used for the
identical U.S. drug to ensure that it meets best practices as established by the FDA and to
distinguish the FDA-approved drug from the non-FDA-approved drug.
119. See 21 U.S.C. § 355 (2012); Liang, supra note 30, at 308–10.
120. United States v. Genendo Pharm., 485 F.3d 958, 960 (7th Cir. 2007).
121. 1500 90-Tablet Bottles, 384 F. Supp. 2d at 1207.  This case was an action by the
government for the seizure and condemnation of the drugs that Genendo attempted to
import.  It took place prior to the criminal case against Genendo but involves the same lot
of prescription drugs.
122. A “new drug application” is the application used to obtain FDA approval for
new, small molecule drugs.
123. Genendo Pharm., 485 F.3d at 961.
124. Id.
125. Id.
126. Id.
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Genendo argued that the deviations from the NDA-approved
requirements were permissible under an FDCA exemption because the
drugs were being shipped to an FDA-authorized repackager.  The
FDCA exemption allows deviations from the FDA-approved labeling
and packaging requirements while they are in transit to a repackager if,
among other things, the repackager and the distributor have a written
agreement that ensures the ultimate drugs will not be adulterated or
misbranded.127  Genendo had a written agreement with the repackager
to this effect.128  However, the exception applies to drugs that can be
brought into compliance, such as drugs that lack a label that the
repackager needs to add.  However, the deviations from the approved
NDA could never be rectified at repackaging because this lot of atorvas-
tatin was packaged at an unapproved facility in Brazil.129  The court
ruled that the drugs were new drugs under the FDCA and could not be
introduced into US interstate commerce.
Similarly, a pharmacist or a physician who introduces a gray market
biologic containing any deviation from the biologic’s BLA into the gray
market, either by reselling it or through any other means, violates the
FDCA.
2. Misbranded Drugs
Under the FDCA, a biologic is misbranded if, among other things,
information on the label is false or misleading, the label lacks informa-
tion required by the FDA-approved BLA or otherwise required under
the FDCA, or certain information is not prominently placed on the
label.130  Required information includes facts regarding the manufac-
turer, packer, distributor, proprietary name, directions for use, warn-
ing, packaging, and precautions about deterioration.131 The biologic is
also misbranded if it is placed in a misleading container or packaging,
or is offered for sale under a misleading name or the name of another
drug.132
The FDCA prohibits introducing into, delivering into, and receiv-
ing in interstate commerce a misbranded biologic or causing the mis-
branding of a biologic.133  It also prohibits the misbranding of a
biologic while it is held for sale after shipment in interstate com-
merce.134  Given that the flow of commerce begins with the manufac-
turer of the biologic and ends with the patient, nearly anyone involved
in the distribution of biologics, including a pharmacist or physician
who holds the drug for use in his practice, may be held liable for deal-
127. Id.
128. Id.
129. Id. at 964.
130. 21 U.S.C. § 352 (2012).
131. 21 U.S.C. § 352(a)–(h).
132. 21 U.S.C. § 352.
133. 21 U.S.C. § 331(a)–(c) (2012).
134. 21 U.S.C. § 331(k).
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ing in a misbranded product, even if someone else caused the mis-
branding in the first place.135
The FDA often prosecutes physicians and pharmacists for selling,
administering, or dispensing misbranded pharmaceuticals, particularly
when patient safety is at issue.  Misbranding is a misdemeanor with a
sentence of imprisonment of not more than one year, a fine of not
more than $1,000, or both.136  However, if the person misbrands with
the intent to defraud or mislead, then such act is a felony, carrying a
sentence of imprisonment for not more than three years, a fine of not
more than $10,000, or both, and debarment.137  A conviction of such
act requires “knowledge of the misbranding and proof of specific intent
to mislead or defraud connected to the misbranding violation.”138  This
can be proved, for instance, if forgery or falsification of any part of the
packaging material occurs.139  Moreover, ramifications for purchasing
misbranded drugs with the intent to defraud or mislead extend beyond
criminal prosecutions.140  Purchasing physicians and pharmacists face
harm to their professional reputations, possibility of losing their
licenses, and potential lawsuits by patients.141  Civil lawsuits can be dev-
astating considering that many, if not most, insurance carriers only pro-
vide malpractice coverage for medications bought in the United States,
so such physicians cannot rely on insurance to protect them if they
purchase an imported or reimported gray market drug.142
Moreover, a physician may be found guilty of introducing mis-
branded drugs with intent to defraud even if he had altruistic inten-
tions.  For instance, in 2008, Dr. Vinod Chandrashekm Patwardhan, a
135. United States v. Evers, 643 F.2d 1043, 1050 (5th Cir. 1981).  The FDCA defines
the circumstances in which a product is placed in interstate commerce to include “(1)
commerce between any State or Territory and any place outside thereof, and (2) com-
merce within the District of Columbia or within any other Territory not organized with a
legislative body.” 21 U.S.C. § 321(b).  It is very rare that a pharmaceutical product on the
market is not “in interstate commerce” under the law while it travels through the distribu-
tion chain. See Key Legal Concepts: Interstate Commerce, Adulterated, and Misbranded, U.S.
FOOD & DRUG ADMIN. (Feb. 9, 2006), http://www.fda.gov/Cosmetics/GuidanceRegula
tion/LawsRegulations/ucm074248.htm.
136. 21 U.S.C. § 333(a)(1) (2012).
137. 21 U.S.C. § 333(a)(2).  If the FDA “debars” an individual, the individual is
prohibited from providing services in any capacity to a person that has an approved or
pending drug product application.  “Services in any capacity” means any services provided
to the drug applicant, regardless of whether related to drug regulations.  That means that
a debarred individual may not provide non-drug-related services to a drug product appli-
cant (e.g., as a landscaper, accountant, etc.) without violating debarment. U.S. FOOD &
DRUG ADMIN., GUIDANCE FOR INDUSTRY: SUBMITTING DEBARMENT CERTIFICATION STATE-
MENTS 4 (1998).
138. United States v. Mitcheltree, 940 F.2d 1329, 1351 (10th Cir. 1991).
139. See United States v. Milstein, 401 F.3d 53, 64 (2d Cir. 2005).
140. 21 U.S.C. § 335a(a)(2) (2012); Yvonne M. McKenzie & Colleen C. Kelly,
Misbranded Drugs—A Danger to Physicians and Patients, LAW360 (Oct. 17, 2013, 4:01 PM),
http://www.law360.com/articles/480500/misbranded-drugs-a-danger-to-physicians-and-
patients.
141. McKenzie & Kelly, supra note 140.
142. Robert Aicher, Off-Shore Injectables Remain Illegal (May 13, 2013) (unpublished
article) (on file with author) (citing Meza v. S. Cal. Physicians Ins. Exch., 62 Cal. Rptr. 2d
91, 92 (Ct. App. 1998)).
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California-licensed physician, was convicted of introducing misbranded
drugs into interstate commerce with the intent to defraud or mislead,
among other things, when he brought pharmaceuticals into the United
States from India and Honduras and administered them to his
patients.143  Dr. Patwardhan frequently treated indigent clients “with-
out much regard for reimbursement.”144  However, when his practice
fell into financial difficulty, he had to change his reimbursement poli-
cies.145  On a trip to India, he learned that cancer medications were far
less expensive there, so he began to purchase them at an Indian phar-
macy and bring them back to the United States, where he administered
them to his patients who could not afford to pay.146
However, Dr. Patwardhan never informed his patients that the
drugs were not FDA-approved.  He told his staff not to give patients
foreign medications for at-home use after a patient’s mother expressed
concern about one label, which was written in Hindi.147  On appeal, the
court found that his actions did not fall under either of the exceptions
to the misbranding statute and upheld his conviction.148
Despite the fact that the judge found it “impossible” to view Dr.
Patwardhan’s crime as “one that was motivated by greed” and also
found Dr. Patwardhan “extraordinar[ily] unlikely to commit another
crime,” Dr. Patwardhan received a sentence of nine months in-home
detention followed by five years of probation, a $10,000 fine, a $600
assessment, and $1,313,634 in restitution.149  In addition, he was pro-
hibited from participating in Medicare, Medicaid, and all federal health
care programs for a period of 12 years.150  However, the state licensing
judge did not revoke Dr. Patwardhan’s license to practice based on his
“misguided altruism.”  This shows a flaw in the system because, even if
Dr. Patwardhan acted in good faith, he still placed his patients at risk by
providing them with medications that may not be safe or effective.  In
balancing “misguided altruism” against the risk Dr. Patwardhan’s con-
duct posed to patients, the scale tips in favor of severely punishing Dr.
Patwardhan, including revoking his medical license, so as to deter other
physicians from engaging in similar behavior.
Dr. William R. Kincaid, a Tennessee physician and president of a
local cancer and blood center, was also charged with receiving mis-
branded drugs in interstate commerce with intent to defraud or mis-
143. Press Release, U.S. Immigration & Customs Enforcement, Southern California
Doctor Charged with Bringing Misbranded Foreign Cancer Drugs into the United States
(Aug. 15, 2008), http://www.ice.gov/news/releases/0808/080815losangeles.htm.
144. Patwardhan v. Inspector Gen., Docket No. C-11-615, at *4 (HHS Dep’t of
Appeals Bd. Dec. 8, 2011).
145. Id.
146. Id.
147. United States v. Patwardhan, 422 F. App’x. 614, 616–17 (9th Cir. 2011).
148. Id. at 616.
149. Patwardhan v. Inspector Gen., at *4.
150. Vinod Chandrashekhar Patwardhan, M.D., Final Decision on Review of
Admin. Law Judge Decision, Docket No. A-12-41, Decision No. 2454 (Dept. of HHS Apr.
10, 2012).
\\jciprod01\productn\N\NDE\29-2\NDE203.txt unknown Seq: 21 20-APR-15 16:47
2015] APPLYING LESSONS FROM THE OPIOID ABUSE EPIDEMIC 395
lead.151  Dr. Kincaid purchased a misbranded version of bevacizumab, a
biologic used to treat cancer, from a Canadian company that obtained
the biologics from foreign sources that were not inspected or approved
by the FDA.152  The drugs were improperly labeled, were sold by dis-
tributors who were not registered with the FDA, and were intended for
distribution in Turkey, India, the European Union, and elsewhere.153
The drugs’ labels were in foreign languages, did not provide dosage
information, and did not express the potency of the drugs in a standard
format.154  After a nurse questioned the medications for bearing labels
in foreign languages, Dr. Kincaid had the misbranded drugs shipped to
a storage facility where he mingled them with FDA-approved drugs
from legitimate sources to avoid further suspicion.155  The cancer med-
ication requires strict temperature conditions, the lack of which could
render it ineffective.156  However, Dr. Kincaid administered the mis-
branded biologics to his patients without their knowledge and without
any assurance that all storage requirements were met, thereby placing
patients’ health and safety at risk in order to increase profits.  Dr. Kin-
caid was sentenced to serve 24 months in a federal prison and a $10,000
fine.157  As a result of his conviction, he also lost his medical license, his
practice, and his reputation.158
Similarly, Dr. Chad Livdahl and his wife and business partner, Dr.
Zahra Karim, were among 29 physicians who were indicted for selling
unapproved botulinum toxin type A, which caused paralysis in four
patients.159  The four victims were hospitalized for severe botulism
poisoning, a result uncommon with the FDA-approved botulinum toxin
type A.160  Dr. Livdhal and Dr. Karim, owners of Toxin Research Inter-
national in Tucson, Arizona, sold unapproved botulinum toxin type A
to more than 200 physicians throughout the United States who adminis-
tered the biologic to their patients.161  Karim and Livdhal obtained the
drugs from a California laboratory that attempted to mimic the FDA-
approved version of the biologic.162  They promoted the product as a
151. Plea Agreement at 1, United States v. Kincaid, 2:12-cr-00116 (E.D. Tenn. Nov.
15, 2012).
152. Id. at 4.
153. Id.
154. Id. (citing 21 C.F.R. §§ 201.56, 610.61(n), (r)).
155. Id.
156. Id.
157. Press Release, U.S. Att’ys Office E. Dist. of Tenn., Johnson City Physician Sen-
tenced to Serve Two Years in Prison for Violations Related to Unapproved Foreign Drugs
(June 11, 2013), http://www.fbi.gov/knoxville/press-releases/2013/johnson-city-physi-
cian-sentenced-to-serve-two-years-in-prison-for-violations-related-to-unapproved-foreign-
drugs.
158. Nate Morabito, Dr. Kincaid Begs Judge for Mercy, Congressman and Sheriff Write
Letters on His Behalf, WSAV (May 31, 2013), http://www.wsav.com/story/22467984/dr-kin
caid-begs-judge-for-mercy-congressman-and-sheriff-write-letters-on-his-behalf.
159. FDA Law Enforcers Crack Down, supra note 17; Christopher Weaver, Illicit Botox
Sparks Alert, THE WALL ST. J. (Dec. 23, 2012), http://online.wsj.com/news/articles/SB100
01424127887324731304578193990868029934.
160. FDA Law Enforcers Crack Down, supra note 17.
161. Id.
162. United States v. Livdahl, 356 F. Supp. 2d 1289, 1292 (S.D. Fla. 2005).
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cheap alternative to the brand-name botulinum toxin type A at work-
shops they conducted, at booths they set up at aesthetic and medical
conventions, at training sessions, and in e-mail and fax communica-
tions.163  The defendants argued that the drug’s packaging stated “For
Research Purposes Only; Not for Human Use,” but the court found that
the disclaimer was an attempt to avoid FDA detection and regulation
when, in fact, the defendants intended for the product to be used on
humans.164  As a result, they were indicted for misbranding a drug by
introducing it into interstate commerce, among other things.165  Dr.
Livdahl was sentenced to nine years in prison, restitution of $345,567,
forfeiture of $882,565, and surrender of his medical license.166  Dr.
Karim received a similar sentence with shorter prison time.167
B. The Prescription Drug Marketing Act of 1987
In 1987, Congress enacted the Prescription Drug Marketing Act of
1987168 (“PDMA”) as an amendment to the FDCA “to protect American
consumers from mislabeled, subpotent, adulterated,169 expired, or
counterfeit pharmaceuticals, which are being dispensed under existing
law and practice, and to restore competitive balance in the market-
place.”170  While the PDMA focuses mainly on the actions of wholesale
distributors, it is important that pharmacists and physicians understand
these requirements for wholesale distributors so they can more easily
spot a gray market biologic.171
The PDMA explicitly prohibits exported prescription drugs from
being reimported back into the United States for sale.172  Therefore,
physicians and pharmacists should be aware of labels that indicate a
163. Id. at 1291–92.
164. Id. at 1291.
165. Id. at 1290; FDA Law Enforcers Crack Down, supra note 17.
166. FDA Law Enforcers Crack Down, supra note 17; Disciplinary Action: Naturopathic
Physicians Medical Board, STATE OF ARIZ. NATUROPATHIC PHYSICIANS MED. BD. (Mar. 23,
2012), available at https://nd.az.gov/sites/default/files/documents/files/Discplinary
%20Actions.pdf.
167. FDA Law Enforcers Crack Down, supra note 17. R
168. Pub. L. No. 100-293, 102 Stat. 95 (1988).
169. An adulterated drug is one that is decomposed; prepared, packed, or held in
insanitary conditions where it may have been contaminated; its container is composed of
any poisonous substance that may render it hazardous to health; its strength, quality, or
purity differs from that which is approved under its BLA; or it is mixed or substituted with
another substance to reduce its quality or strength, among other things.  21 U.S.C. § 351
(2012).
170. RxUSA Wholesale v. Dep’t of Health & Human Servs., 467 F. Supp. 2d 285,
290 (E.D.N.Y. 2006) (citing H.R. REP. NO. 100-76, at 17 (1987)) (internal quotation mark
omitted).
171. See Prescription Drug Marketing Act, 21 U.S.C. §§ 331(t), 333(b), 353(c)–(e),
381(d) (2012); 21 C.F.R. pts. 203 & 205 (2013).
172. 21 U.S.C. § 381(d)(3).  The only exception is if the drugs are sent to the initial
owner or consignee of the drug for further processing and will then be exported again.
Please note that prescription drugs containing insulin that are manufactured in the
United States and then exported from being reimported back into the country may not
be reimported back into the U.S. even if they are processed and re-exported unless such
drugs are necessary for emergency medical care.  21 U.S.C. §§ 381(d)(1)–(2).
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biologic is intended for a foreign market.  However, the federal govern-
ment has not strictly enforced this prohibition due to a lack of
resources to patrol the millions of drug shipments that enter the
United States each year.  This is a major problem in gray market
enforcement.173
Additionally, the PDMA prohibits pharmacists or physicians within
charitable organizations, such as hospitals or other “health care enti-
ties”174 from offering, selling, purchasing, or trading any prescription
drugs that are obtained at a reduced rate due to their nonprofit status
under the Robinson Patman Act, except in limited circumstances.175
This statute does not prohibit hospitals or health care entities from sell-
ing, purchasing, or trading a medication for emergency medical rea-
sons, which is often used as the justification to purchase gray market
medications in short supply.176  Yet, pharmacists and physicians may be
held liable under other legal doctrines for purchasing, administering,
or dispensing gray market pharmaceuticals, such as the misbranding
regulations, so it is unwise to rely on this exception.
The PDMA also prohibits anyone from knowingly selling, purchas-
ing, or trading, or offering to sell, purchase, or trade a prescription
drug sample.177  Although the PDMA allows charitable institutions to
receive sample drug donations for dispensing to patients of the charita-
ble institution, the sample medication must be in its original, unopened
173. Prescription Drug Re-Importation Question and Answer Sheet, AARP, http://assets
.aarp.org/www.aarp.org_/articles/international/ReimportationQA.pdf (last visited Aug.
11, 2013). Agents from Customs and Border Protection (“CBP”), a division of the U.S.
Department of Homeland Security, are responsible for inspecting incoming drug pack-
ages and notifying the FDA.  FDA investigators noted that there are only 16.9 full time
FDA employees responsible for covering all packages in international mail facilities in the
United States to search for incoming gray market drugs. PEW HEALTH GROUP, supra note
71; HHS TASK FORCE ON DRUG IMPORTATION, REPORT ON PRESCRIPTION DRUG IMPORTATION
56 (Dec. 2004), http://archive.hhs.gov/importtaskforce/Report1220.pdf.
174. A health care entity is defined as any person that provides diagnostic, medical,
surgical, or dental treatment or chronic or rehabilitative care, but does not include any
pharmacy or wholesale distributor. 21 C.F.R. § 203.3(q).
175. 21 C.F.R. § 203.20.  A charitable organization is defined as a nonprofit hospi-
tal, health care entity, organization, institution, foundation, association, or corporation
that has been granted nonprofit status under section 501(c)(3) of the Internal Revenue
Code.  21 C.F.R. § 203.3(f).  This regulation also prohibits solicitations made by gray mar-
ket distributors to hospitals, health care entities, and nonprofits.  21 C.F.R. § 203.20.  The
limited circumstances for which the prohibition does not apply can be found in 21 C.F.R.
§ 203.22 and 21 C.F.R. § 203.23.
176. 21 C.F.R. § 203.22. See also 21 C.F.R. § 203.3(m).  Emergency medical reasons
include, but are not limited to, transfers of a prescription drug between health care enti-
ties or from a health care entity to a retail pharmacy to alleviate a temporary shortage of a
prescription drug arising from delays in or interruption of regular distribution schedules;
sales to nearby emergency medical services, i.e., ambulance companies and fire fighting
organizations in the same State or same marketing or service area, or nearby licensed
practitioners, of drugs for use in the treatment of acutely ill or injured persons; provision
of minimal emergency supplies of drugs to nearby nursing homes for use in emergencies
or during hours of the day when necessary drugs cannot be obtained; and transfers of
prescription drugs by a retail pharmacy to another retail pharmacy to alleviate a tempo-
rary shortage; but do not include regular and systematic sales to licensed practitioners of
prescription drugs that will be used for routine office procedures.
177. 21 U.S.C. § 353(c)(1) (2012).
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packaging with its label intact, and inspected by a licensed health care
practitioner or state-registered pharmacist to confirm that the drug is
not adulterated or misbranded.178  If the drug does not meet the pack-
aging and labeling requirements, the recipient of the sample must not
dispense it to patients and must dispose of the drug by destroying it or
returning it to the manufacturer.179  Violations of this provision are
punishable by up to ten years imprisonment.180  Physicians and phar-
macists should be careful to check the label on medications to ensure
they are not intended as samples.
The PDMA requires all drug distributors to be licensed by the state
from which the drugs are to be shipped, and such state licensing sys-
tems must meet federal regulations on minimum requirements for
drug storage and security, and for the treatment of returned, damaged,
and outdated prescription drugs.181  Many gray market distributors
avoid the licensing process altogether to increase the likelihood that
they can engage in illegal activities without scrutiny from state authori-
ties.  Pharmacists and physicians should only purchase biologics from
state-licensed distributors.
C. Drug Quality and Security Act
The federal Drug Quality and Security Act (“DQSA”), enacted on
November 27, 2013, established standards to facilitate tracing of drug
products through the pharmaceutical supply chain, including requiring
that all pharmaceuticals have product identifiers182 and documentation
of the entire transaction history from the manufacturer to the health
care practitioner or pharmacist dispensing or administering the medi-
cation.183  Therefore, when the DQSA goes into effect on January 1,
2015, pharmacists and physicians should not accept biologics lacking
product identifiers or without proper documentation.184  Moreover,
the DQSA requires that wholesale distributors operating in states with-
out licensure requirements obtain a license from the Department of
Health and Human Services (“HHS”).  Consequently, there is no rea-
son to accept a biologic from an unlicensed distributor with these rules
in place.
178. 21 C.F.R. §§ 203.39(a), (c) (2012).
179. 21 C.F.R. § 203.39(d).
180. 21 U.S.C. § 333(b)(1)(B) (2012); U.S. DEP’T OF JUSTICE, UNITED STATES ATTOR-
NEYS’ MANUAL § 113 (1997), http://www.justice.gov/usao/eousa/foia_reading_room/
usam/title4/civ00113.htm.
181. 21 U.S.C. § 353(e)(2)(A); 21 C.F.R. §§ 205.4, 205.5, 205.50; U.S. FOOD &
DRUG ADMIN., PRESCRIPTION DRUG MARKETING ACT OF 1998: CHAPTER 2 FDA AUTHORITY,
REGULATORY PROCEDURES MANUAL § 2-2-27 (July 2012), http://www.fda.gov/downloads/
ICECI/ComplianceManuals/RegulatoryProceduresManual/UCM074340.pdf.
182. “The term ‘product identifier’ means a standardized graphic that includes, in
both human-readable form and on a machine-readable data carrier that conforms to the
standards developed by a widely recognized international standards development organi-
zation, the standardized numerical identifier, lot number, and expiration date of the
product.”  21 U.S.C § 360eee(14) (2012).
183. See 21 U.S.C §§ 582(b)–(e) (2012).
184. Id.
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D. Health Care Fraud
The federal criminal health care fraud statute, which is part of the
Health Insurance Portability and Accountability Act of 1996 (“HIPAA”),
prohibits,
[K]nowingly and willfully execut[ing], or attempt[ing] to execute,
a scheme . . . to defraud any health care benefit program; or to
obtain, by means of false or fraudulent pretenses, representations,
or promises, any of the money or property owned by, or under the
custody or control of, any health care benefit program in connec-
tion with the delivery of or payment for health care benefits,
items, or services . . . .185
This statute covers fraud upon private payers and public insurers, such
as Medicaid, Medicare, and other state-funded health programs.186
Government-funded health care programs, such as Medicare and
Medicaid, as well as most state-funded health care programs, do not
cover non-FDA-approved new drugs or misbranded drugs.187  Physi-
cians and health care providers must submit claims for reimbursement
for administered or dispensed drugs that represent that such drugs
were FDA-approved drugs.188  If a physician submits such a form for a
non-FDA-approved new or misbranded drug to a Medicare or Medicaid
program and certifies that such drug is an FDA-approved drug, he is
making a false statement.  Moreover, if he obtains the drug at a dis-
counted price and submits a claim for the FDA-approved drug, which
sells at a higher price, he is using fraudulent pretenses to obtain money
from a health care benefit program in connection with the delivery of,
or payment for, health care benefits, items, or services.
In United States v. Shrum,189 Dr. Kelly Dean Shrum, a physician
licensed to practice in Arkansas, was convicted of health care fraud.  Dr.
Shrum purchased non-FDA-approved intrauterine devices (“IUDs”)
from purported Canadian internet pharmacies at deeply discounted
prices, administered such devices to patients, and billed the Arkansas
Medicaid Program for the FDA-approved version, making a profit in
reimbursements.190  The claims he submitted to the Arkansas Medicaid
Program included false representations.191  Therefore, the court found
that he knowingly and willfully executed a scheme to defraud the
Arkansas Medicaid Program and obtained, by means of fraudulent pre-
tenses and representations, money under the custody and control of
185. 18 U.S.C. § 1347(a) (2012).
186. ROBERT FABRIKANT & PAMELA H. BUCY, HEALTH CARE FRAUD: ENFORCEMENT AND
COMPLIANCE § 3.02[12A] (2013).
187. 42 U.S.C. §§ 1396r-8(k)(2)–(3), (6) (2012); 42 U.S.C. § 1395w-
102(e)(4)(A)(ii) (2012); United States ex rel. Palmieri v. Alpharma, Inc., 928 F. Supp. 2d
840, 843 (D. Md. 2013).
188. Plea Agreement at 4, United States v. Kincaid, 2:12-cr-00116 (E.D. Tenn. Nov.
15, 2012).
189. United States v. Shrum, No. 4:09cr00295-01 JMM, 2011 WL 4903082 *1 (E.D.
Ark. Oct. 3, 2011).
190. Id. at *2, 6.
191. Id. at *6.
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the Arkansas Medicaid Program in connection with the delivery of or
payment for health care benefits, items, or services.192  As a result, he
was ordered to forfeit $75,000 of proceeds from the health care
fraud.193  Additionally, the FDA permanently debarred him from pro-
viding medical services to patients in any capacity with prescription
drugs.194
Similarly, Dr. Isabella Martire, a Maryland-licensed physician, was
charged with introducing a misbranded drug into interstate commerce
and health care fraud because she administered cancer drugs that were
manufactured in the United Kingdom and intended for distribution in
Turkey, but billed US government health care programs for the FDA-
approved drug.195  Dr. Martire sought reimbursement from Medicare,
Medicaid, Tricare, federal employee health benefit plans, and private
health insurers for the cost of the drugs, making a profit of at least
$790,600.196  Dr. Martire was forced to repay $514,000 to government
health care programs.197
E. Other Charges
In addition to charges under the FDCA, the PDMA, and the health
care fraud statute, physicians and pharmacists who participate in the
gray market may be criminally charged with conspiracy; bank, mail, or
wire fraud; and false statements.
1. Conspiracy
It is a federal offense for two or more persons to conspire either to
commit any offense against the United States or to defraud the United
States, or any agency thereof, in any manner or for any purpose.198
The penalty for such act is a maximum fine of $250,000, a maximum
prison sentence of five years, or both.199  In Hammerschmidt v. United
States, the Supreme Court defined “defraud” as follows:
To conspire to defraud the United States means primarily to cheat
the Government out of property or money, but it also means to
interfere with or obstruct one of its lawful governmental functions
192. Id.
193. Press Release, U.S. Dep’t of Justice, E. Dist. of Ark., Pine Bluff Doctor Con-
victed of Misbranding and Health Care Fraud, (Nov. 17, 2010), http://www.justice.gov/
usao/are/news/2010/November/shrumguilty_HCF_111710.pdf.
194. Kelly Dean Schrum: Debarment Order, 77 Fed. Reg. 51030, 51031 (Aug. 23,
2012) (Order).
195. STATE OF MD, ANNUAL REPORT OF THE MEDICAID FRAUD CONTROL UNIT AND
OFFICE OF THE INSPECTOR GENERAL, 8 (2012), http://dlslibrary.state.md.us/publications/
Exec/DHMH/HG2-611(a)_2012.pdf; Press Release, U.S. FOOD & DRUG ADMIN. Office of
Criminal Investigations, Laurel Oncologist Pleads Guilty to Purchasing Misbranded
Drugs, (Aug. 8, 2011), http://www.fda.gov/ICECI/CriminalInvestigations/ucm267356
.htm.
196. Press Release, U.S. FOOD & DRUG ADMIN. Office of Criminal Investigations,
supra note 195.
197. Id.
198. 18 U.S.C. § 371 (2012).
199. Id.
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by deceit, craft or trickery, or at least by means that are dishonest.
It is not necessary that the Government shall be subjected to prop-
erty or pecuniary loss by the fraud, but only that its legitimate offi-
cial action and purpose shall be defeated by misrepresentation,
chicane or the overreaching of those charged with carrying out
the governmental intention.200
Therefore, proof that the United States has been defrauded under
this section does not require any showing of monetary or proprietary
loss.201  If the defendant and others have engaged in dishonest prac-
tices in connection with a program administered by an agency of the
government, it constitutes a fraud on the United States.202
The element of intent is met if the defendant possesses the intent
(a) to defraud, (b) to make false statements or representations to the
government or its agencies in order to obtain property of the govern-
ment, or (c) that the defendant performed acts or made statements
that he knew to be false, fraudulent or deceitful to a government
agency, which disrupted the function of the agency or of the govern-
ment.203  The government is not required to prove the statements ulti-
mately resulted in any actual loss to the government of any property or
funds, only that the defendant’s activities impeded or interfered with
legitimate governmental functions.204
In United States v. Gallant Pharma International, Inc., the defendants
were charged with conspiracy, among other things.205  The defendants
included Gallant Pharma International, an unlicensed distribution
company located in Virginia, and all of Gallant’s employees, which
included two directors, four sales representatives, and two office manag-
ers, as well as a physician who purchased misbranded biologics from
Gallant.206  Gallant held itself out as a Canadian company but obtained
botulinum toxin type A, cancer biologics, and other prescription drugs
from Switzerland, Turkey, and the United Arab Emirates, selling the
misbranded drugs in the United States.207
Defendant Anoushirvan Sarraf, a Virginia-licensed physician,
allowed the other defendants to (1) lease office space within his medi-
cal practice, (2) ship the misbranded drugs to Dr. Sarraf’s office, and
(3) ship the misbranded drugs to physicians, medical practices, and
200. Hammerschmidt v. United States, 265 U.S. 182, 188 (1924).
201. United States v. Conover, 772 F.2d 765, 770 (11th Cir. 1985).
202. United States v. Gallup, 812 F.2d 1271, 1276 (10th Cir. 1987).
203. See United States v. Puerto, 730 F.2d 627 (11th Cir. 1984); United States v.
Tuohey, 867 F.2d 534 (9th Cir. 1989); United States v. Sprecher, 783 F. Supp. 133, 156
(S.D.N.Y. 1992).
204. See Sprecher, 783 F. Supp. at 156.
205. United States v. Gallant Pharma Int’l, Inc., Indictment, Criminal No. 1:13-CR-
130, at *1 (E.D. Va. Mar. 27, 2013).  Other charges included importation contrary to law,
introduction of misbranded drugs, unlicensed medical wholesaling, wire fraud, and mon-
etary transactions with criminally derived proceeds. Id.
206. Id. at *1, 7–9.
207. Id. at *1, 5.
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hospitals throughout the country from his office.208  Dr. Sarraf also pur-
chased drugs from Gallant to administer to his patients.
The other defendants sent solicitations advertising brand-name
drugs at deeply discounted prices, an example of which is in Figure 2
below, but they actually sold and delivered misbranded medications.209
The court found that the defendants conspired to: (a) fraudulently and
knowingly import misbranded drugs into the U.S. in violation of the
FDCA; (b) engage in wholesale distribution without a Virginia license;
(c) introduce misbranded drugs into interstate commerce with the
intent to defraud; (d) knowingly and with the intent to defraud, devise
a scheme and artifice to defraud, and obtain money and property by
false or fraudulent pretenses, and transmit wire communications in
interstate and foreign commerce; and (e) defraud the United States by
impeding, impairing, and defeating the lawful functions of the FDA to
protect the health and safety of the public.210  As a result, all but two of
the defendants were indicted and pleaded guilty, and sentencing is still
pending as of March 2014.211  They could face the following sentences
based on their convictions: 212
Importation contrary to law Maximum of 20 years
Wire fraud Maximum of 20 years
Monetary transactions with Maximum of 10 yearscriminally derived proceeds
Defraud of the FDA Maximum of 5 years
Introduction of misbranded drugs Maximum of 3 yearsinto interstate commerce
Unlicensed medical wholesaling Maximum of 3 years
On May 7, 2014, the two defendants who did not plead guilty,
Anoushirvan Sarraf and Eva Pritchard, were convicted by a federal jury
on charges of conspiracy related to their roles in the diversion
scheme.213
Therefore, physicians and pharmacists should be skeptical of solici-
tations offering medications below market price and contact manufac-
turers when doubts arise as to distributor or product legitimacy.
208. Id. at *12.
209. Id. at *14.
210. Id. at *10–11.
211. Id. at *1.
212. Press Release, U.S. Att’ys Office, Eastern District of Virginia, Eleven Charged
in Alleged Illegal Pharmacological Import and Distribution Scheme, (Aug. 7, 2013), avail-
able at http://www.justice.gov/usao/vae/news/2013/08/20130807hudanr.html.
213. Press Release, U.S. Dep’t of Justice, Aphrodite Advanced Esthetic & Skin Care
Clinic Received Illegal Imports For Gallant Pharma, Which Sold Over $10 Million Of
Non-FDA-Approved Chemotherapy And Cosmetic Drugs In The U.S., (May 7, 2014),
http://www.fda.gov/ICECI/CriminalInvestigations/ucm397123.htm.
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2. Bank, Mail, and Wire Fraud
Bank fraud, which is a federal offense against the United States,
occurs if an individual “knowingly executes or attempts to execute a
scheme . . . to defraud a financial institution[ ] or to obtain any of the
money[ ], funds, credits, assets, . . . or other property owned by the
bank by means of false or fraudulent pretenses . . . .”214  The sentence
for bank fraud is a maximum fine of $1,000,000, a maximum prison
sentence of 30 years, or both.215
Mail fraud, which is a federal offense against the United States,
occurs if an individual devises or intends to devise a scheme to defraud
or obtain money or property by means of false or fraudulent pretenses,
representations, or promises by utilizing the mail.216  The sentence for
such an act is a maximum fine of $250,000, a maximum of 20 years
imprisonment, or both.217
Wire fraud, which is a federal offense against the United States,
occurs if an individual devises or intends “to devise a scheme to
defraud, or for obtaining money or property by means of false or fraud-
ulent pretenses, representations, or promises,” and “transmits or causes
to be transmitted by means of wire . . . in interstate . . . commerce, any
writings . . . for the purpose of executing such scheme . . . .”218  The
sentence for such an act is a maximum fine of $1,000,000, imprison-
ment of not more than 30 years, or both.219  Charges of conspiracy, and
bank, mail, and wire fraud are common as a result of gray market
schemes due to the multiple parties involved and transactions entailing
payment in exchange for shipment of goods.
For instance, pharmacist Andrew J. Strempler was charged with
both conspiracy to commit mail fraud and wire fraud, for actually com-
mitting mail fraud and wire fraud, and for selling misbranded
pharmaceuticals from his Canadian pharmacy, RxNorth.  RxNorth was
an internet, mail, and telephone order pharmacy that sold to residents
of the United States.220  Although the FDA warned Strempler that sales
of drugs were illegal in the United States unless the drugs were FDA-
approved,221 Strempler continued to sell the drugs in the United
States, falsely representing that RxNorth was selling safe medications in
compliance with US regulations.  In reality, Strempler obtained the
drugs from other countries without properly ensuring safety or authen-
ticity, filled prescriptions for US consumers in the Bahamas, and then
had the packages shipped to the United States.222
214. 18 U.S.C. § 1344 (2012).
215. Id.
216. 18 U.S.C. § 1341 (2012).
217. Id.
218. 18 U.S.C. § 1343 (2012).
219. Id.
220. Press Release, U.S. FOOD & DRUG ADMIN. Office of Criminal Investigations,
Internet Pharmacy Owner Charged in $95 Million Fraud Scheme (June 14, 2012), http://
www.fda.gov/ICECI/CriminalInvestigations/ucm309438.htm.
221. Id.
222. Id.
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3. False Statements
Under the federal false statements statute, individuals are prohib-
ited from knowingly and willfully making material false statements on
matters within the jurisdiction of the executive, legislative, or judicial
branch of the federal government.223  A matter is considered “material”
if “it has a natural tendency to influence, or is capable of influencing,
the decision of the [individual or entity] to [whom] it [is]
addressed.”224  A matter is “within the jurisdiction of” a federal entity
“when it has the power to exercise authority in a particular situation”
and “may exist when false statements [are] made to state or local gov-
ernment agencies receiving federal support or subject to federal regula-
tion.”225  A violation of this provision is punishable by imprisonment
for not more than five years and a fine of not more than $250,000 for
individuals or $500,000 for corporations.226
Dr. Gayle Rothenberg, a physician licensed in Texas, was convicted
of making false statements to an agent of the United States govern-
ment, in addition to misbranding a biologic while it was being held for
sale with intent to defraud or mislead.227  Dr. Rothenberg ordered and
administered misbranded botulinum toxin type A to more than 170
patients despite the fact that it was labeled with the warning “For
Research Purposes Only, Not for Human Use.”228  Dr. Rothenberg also
misrepresented to patients that they were receiving injections of the
FDA-approved drug.229  On January 20, 2005, FDA agents traveled to
Dr. Rothenberg’s clinic and spoke to her about whether any of the mis-
branded medication had been ordered and used on patients in her
medical clinic.230  In response, Dr. Rothenberg confirmed that the
non-approved product had been ordered but falsely stated that it had
only been administered to friends and family.231  During a second visit
from FDA agents, Dr. Rothenberg stated that the product had been
used on approximately 210 of her patients without her knowledge or
approval.  However, the FDA found that Dr. Rothenberg was aware all
along that her patients were receiving a non-FDA-approved version of
the biologic that was not intended for human use.232  As a result, Dr.
223. 18 U.S.C. § 1001 (2012).
224. United States v. Staad, 636 F.3d 630, 638 (D.C. Cir. 2011) (quoting Neder v.
United States, 527 U.S. 1, 16 (1999)); see also United States v. Garcia-Ochoa, 607 F.3d 371,
375 (4th Cir. 2010).
225. United States v. Ford, 639 F.3d 718, 720 (6th Cir. 2011) (quoting United States
v. Rodgers, 466 U.S. 475, 479 (1984)) (internal quotation marks omitted).
226. 18 U.S.C. § 1001 (2012).
227. Press Release, U.S. Att’ys Office, S. Dist. of Tex., Local Physician Sentenced for
Injecting Patients with Fake Botox (Apr. 16, 2010), http://www.justice.gov/usao/txs/
1News/Releases/2010%20April/041610%20Rothenberg.htm.
228. Id.
229. Gayle Rothenberg: Debarment Order, 76 Fed. Reg. 69,272, 69,273 (Nov. 8,
2011) (order).
230. Id.
231. Id.
232. Gayle Rothenberg: Proposal to Debar, Notice of Opportunity for Hearing,
Docket No. FDA-2011-N-0444 (July 29, 2011).
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Rothenberg was sentenced to five and a half months in federal prison,
three years of supervised release, and $96,426 in restitution to her
patients.233  In addition, the FDA permanently debarred Dr. Rothen-
berg from providing services in any capacity to a person with an
approved or pending drug product based on her felony convictions
related to the regulation of a drug product under the FDCA.234
In sum, while a simple misbranding charge is only a misdemeanor,
it is possible for a physician or pharmacist to be charged with various
felonious offenses simultaneously, resulting in imprisonment, steep
monetary fines, and debarment, regardless of whether their actions
were profit-driven, as in the case of Gallant Pharma, or altruistic, as in
the case of Dr. Patwardhan.  Given that the FDA has stated that it does
not have the resources to adequately pursue gray market bad actors,
states must undertake their own investigations and prosecutions.
IV. EFFORTS TO PROTECT PATIENTS FROM GRAY MARKET BIOLOGICS:
RECOMMENDATIONS FOR EDUCATION AND ENFORCEMENT
Although the FDA is responsible for protecting the health and
safety of Americans by regulating drug approval and distribution in the
United States, it cannot manage all aspects of the supply chain.  FDA
efforts to implement and enforce federal laws are well-intentioned;
however, they inadequately reduce the threat posed by gray markets.
States have broad police powers in regulating health professionals’ dis-
pensing and administering of drugs.235  Where there are weaknesses in
enforcement at the federal level, states and professional groups should
intervene, drawing lessons and resources from state and professional
responses to controlled substance diversion.
Prescription drug abuse often results from improper prescribing or
dispensing by physicians and pharmacists, either due to a lack of educa-
tion on controlled substances or intentional bad behavior.  As a result,
many state legislatures or medical boards have required prescriber edu-
cation in safe prescribing and abuse prevention.236  States have also
increased investigation and enforcement efforts, including prosecuting
intentional bad actors and implementing professional sanctions and
rehabilitation for negligent actors.  Additionally, professional associa-
tions have released best practice guidelines for health care practitioners
and have instituted consumer awareness campaigns.237  These com-
bined federal, state, professional, and corporate efforts have yielded
reductions in diversion, abuse, and consumer harm.238  As manufactur-
233. Press Release, U.S. Att’ys Office, S. Dist. of Tex., supra note 7.
234. Gayle Rothenberg: Debarment Order, 76 Fed. Reg. at 69,273.
235. Robinson v. California, 370 U.S. 660, 664–65 (1962); Minnesota ex rel. Whip-
ple v. Martinson, 256 U.S. 41, 45 (1921).
236. See STRATEGIES TO STOP THE EPIDEMIC, supra note 9.
237. NAT’L ALLIANCE FOR MODEL STATE DRUG LAWS, PRESCRIPTION DRUG ABUSE,
ADDICTION AND DIVERSION: OVERVIEW OF STATE LEGISLATIVE AND POLICY INITIATIVES 7
(2014), available at http://www.namsdl.org/library/6D4B39ED-65BE-F4BB-A67AEA9E5
3B140A9/.
238. See supra note 10 and accompanying text.
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ers produce alternatives to controlled substances that are less appealing
to would-be abusers, such as biologics, states and professionals must
take parallel action to reduce the proliferation of the gray market for
biologics.  Many of the activities can be adjusted and applied to address
the diversion of biologics to the gray market.
A. State Intervention
As states work to stem the epidemic of controlled substance diver-
sion and abuse, law enforcement, public health agencies, and health
care providers must cooperate to simultaneously establish and enforce
clear rules supported by meaningful professional and criminal penal-
ties, in order to effectively deal with gray market biologics.239  State law
enforcement and licensing boards are an important component of
pressuring gray market participants to cease trafficking in gray market
medications and educating licensed health care providers about the
dangers of gray market medications.240  States are in the best position
to deal with potential drug-related health and safety threats and may
employ a combination of federal and state laws to patch holes in the
closed system of distribution of biological pharmaceuticals.241
1. Mandatory Education
No health care practitioner should purchase gray market medica-
tions because the risk is too high.  However, many simply are not prop-
erly educated on the risks involved or even how to spot a gray market
biologic.  States have the authority to impose requirements on licensed
professionals in order to protect the health, safety, and welfare of the
public, including the right to mandate education.242
Many states have adopted, through legislation or regulation, educa-
tion requirements regarding pain management, safe prescribing of con-
trolled substances, screening for substance use disorders, substance
abuse prevention, and use of state prescription monitoring programs in
order to reduce the prescription drug abuse epidemic.243  For instance,
Kentucky-licensed physicians complete 7.5 percent of their required
continuing education courses on the use of prescription drug monitor-
ing programs, pain management, or addiction disorders.244  Massachu-
setts requires all prescribers to complete education relating to “effective
pain management, identification of patients at high risk for substance
239. Liang, supra note 30, at 312–313. R
240. Gray Market, Black Heart, supra note 32. R
241. Kane, supra note 33 (noting that the FDA’s Office of Criminal Investigations R
looks into complaints about blatant safety concerns in the gray market but the agency
defers to the states to do the bulk of regulation).
242. United States v. E. C. Knight Co., 156 U.S. 1, 11 (1895).
[T]he power of a State to protect the lives, health, and property of its citizens, and to
preserve good order and the public morals . . . is a power originally and always belonging
to the States, not surrendered by them to the general government, nor directly restrained
by the Constitution of the United States, and essentially exclusive.
243. PRESCRIPTION NATION, supra note 36. R
244. Ky. Rev. Stat. Ann. § 218A.205 (LexisNexis 2013).
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abuse, and counseling patients on the side effects, addictive nature, and
proper storage and disposal of prescription medications.”245  Courses
on the risks of biologic fraud and diversion may readily be incorporated
into existing course offerings, which already address other forms of
fraud and diversion.
Similarly, as other states enact education mandates to reduce con-
trolled substance diversion and abuse, they must ensure the require-
ment and curricula address fraud, diversion, and patient safety related
to the gray market for biologics.  Such topics could be included in eth-
ics courses or as part of safe prescribing and fraud and abuse detection
requirements.246 Virginia mandates that physicians complete sixty
hours of “continued competency requirements” every two years.247
Thirty of these hours may be in areas such as ethics, standards of care,
patient safety, and patient communication, all of which lend themselves
well to a discussion of gray market biologics.248  Such specific training
surrounding the physician and pharmacist role in ensuring the safety
and proper use of medications, including biologics, is needed in all
states.
It is equally important that education for physicians and pharma-
cists also address the adulteration of prescription drugs.  They must
remain vigilant and mindful to the concerns brought to them by
patients.  If a drug is not having the positive effects that it once had, or
a medicine tastes different than it has in the past, or an injection sud-
denly begins to hurt, physicians and pharmacists must consider that the
drug may be spoiled or counterfeit.249
Once professionals are educated, professional boards must revoke
professionals’ licenses for dispensing or administering gray market bio-
logics because, at that point, professionals are aware of the risks.  Their
actions become intentional and knowing.  Therefore, they must be
prosecuted.
2. Investigation and Professional Sanctions
State pharmacy and medical boards are responsible for overseeing
the entities that buy, sell, prescribe, and dispense prescription drugs,
including pharmacists, distributors (in states in which licensure is
required), and physicians.  They serve a judicial function by conducting
investigations and hearings on alleged wrongdoings.  Hearings resem-
245. MASS. GEN. LAWS ch. 94C, § 18(e) (2013).
246. See, e.g., N.M. STAT. ANN. § 24-2D-5.2 (2012) (requiring quarterly prescription
drug misuse and overdose prevention and pain management advisory council meetings to
discuss education of professional prescribers in New Mexico, among other issues).
247. Continued Competency Requirements for Renewal of an Active License, 18
VA. ADMIN. CODE § C85-20-235(A) (2012).
248. Id.
249. Louis A. Ling, While We Are Waiting: Imagining and Creating a Safe Drug Supply
While We Await the Coming of the Radio Frequency Identification Track-and-Trace System, 19 J.
PHARMACY PRAC. 153, 158–59 (2006).
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ble civil and criminal court proceedings,250 or, at the very least, an
administrative hearing, when deciding to revoke or suspend the license
of a pharmacist or physician.  They must investigate wrongdoers and
determine the proper punishment in order to deter future bad acts.  If
an investigation shows that a gray market participant has acted negli-
gently, at a minimum, the practitioner must receive professional sanc-
tions, such as a revocation of a license or suspension and rehabilitation.
After being involved in both gray market biologic diversion and
controlled substance diversion, Erick Falconer, a physician licensed in
Missouri, Illinois, and Arizona, pleaded guilty to making false state-
ments to federal agents regarding his purchase of misbranded botu-
linum toxin type A from a foreign unlicensed drug wholesaler, some of
which had counterfeit packaging.251  Dr. Falconer made over fifty sepa-
rate purchases of the Turkish version of botulinum toxin type A at a
discounted price that was over thirty percent below the US market
rate.252  However, during an interview with FDA special agents, Dr. Fal-
coner said he only made three purchases of the illegal drugs from this
unlicensed foreign wholesaler.  After receiving notice that Dr. Falconer
would be charged with making a material false statement and represen-
tation to special agents of the FDA, the Illinois Department of Financial
and Professional Regulations (“Illinois board”) found that Dr. Fal-
coner’s continued practice of medicine constituted an immediate dan-
ger to the public, and on December 3, 2013, the Illinois board
suspended Dr. Falconer’s license.253  Ten days later, it issued a tempo-
rary restraining order, which reinstated his medical license, but
restricted him to the practice of emergency medicine only.254  He was
also prohibited from administrating botulinum toxin type A.255
Additionally, the Missouri State Board of Registration for Healing
Arts has a formal complaint pending against Dr. Falconer, alleging that,
in addition to making false statements, he repeatedly failed to meet the
250. In an administrative disciplinary action, the burden of proof varies in different
states.  Some states require a preponderance of the evidence standard in order to sustain
an administrative prosecution.  Preponderance of the evidence occurs when the fact-
finder is satisfied that the facts are more likely true than not true.  Other states require a
stronger clear and convincing evidence standard to prove administrative violations.  In a
clear and convincing evidence standard, the fact-finder must have a firm believe that the
allegations are true, although reasonable doubt may still exist. See Dale J. Atkinson, Legal
Briefs: Burden May Be Burdensome, NAT’L ASS. OF BDS. OF PHARMACY (Mar. 21, 2012, 4:06
PM), http://www.nabp.net/news/legal-briefs-burden-may-be-burdensome (last visited
Feb. 17, 2014); see also 29 AM. JUR. 2d, Evidence § 173.
251. Press Release, U.S. Att’ys Office, E. Dist. of Mo., Local Doctor Pleads Guilty to
Making False Statement to Agent (Nov. 6, 2013), http://www.justice.gov/usao/moe/
news/2013/november/falconer_erick.html.
252. Id.
253. In the Matter of Erick A. Falconer, MD-13-1181, Order Rescinding Summary
Suspension and Interim Findings of Fact, Conclusion of Law and Order for Summary
Practice Restriction, Ariz. Med. Bd., http://azmd.gov/GLSuiteWeb/Repository/0/0/2/
9/a3d897c3-a290-4947-8209-fd2d65a78361.pdf.
254. Id. at 3.
255. Id.
\\jciprod01\productn\N\NDE\29-2\NDE203.txt unknown Seq: 35 20-APR-15 16:47
2015] APPLYING LESSONS FROM THE OPIOID ABUSE EPIDEMIC 409
standard of care.256  He was also previously disciplined by the Missouri
Bureau of Narcotics and Dangerous Drugs for “multiple violations relat-
ing to safeguarding, dispensing, record-keeping, and failing to provide
effective controls to guard against the diversion of controlled sub-
stances . . . .”257  As a result, the Missouri board also suspended Dr.
Falconer’s license. Arizona’s board took into consideration the Illinois
and Missouri board decisions, and found that Dr. Falconer’s actions
constituted unprofessional conduct under Arizona law.258  Although
the Arizona board summarily suspended Dr. Falconer’s license to prac-
tice medicine in Arizona, the Board later removed its suspension but
restricted Dr. Falconer’s license so that he could only practice emer-
gency medicine through his practice group and was prohibited from
administering botulinum toxin type A.259  It is surprising and discon-
certing that, given the egregious nature of Dr. Falconer’s activities, his
license was not revoked in all three states.
State legislatures must ensure that professional licensing boards
have adequate resources for carrying out their investigation and
enforcement responsibilities and that they be held accountable for ful-
filling their responsibilities to vigilantly protect the public from the
harms associated with gray market biologics.
3. Criminal Enforcement
To curb the dangerous practices of non-compliant pharmacists and
physicians and eventually drive them out of the market, meaningful
criminal sanctions must be imposed on intentional bad actors.
When law enforcement or licensing boards investigate and discover
that they are dealing with a non-compliant physician or pharmacist
whose behavior is knowing and willful, the next step should be to refer
the case for prosecution to the full extent of the law.  When state law
requires physicians and pharmacists to be properly educated regarding
the risks and harms to consumers associated with the gray market, the
incidences of unknowing, negligent gray market participation can be
expected to decline to near zero.  It is likely that only the egregious
actors who knowingly and intentionally participate in gray market activi-
256. Id. Additionally, Dr. Falconer allegedly (1) “repeatedly enticed and misled
patients into false expectations to solicit business;” (2) “repeatedly failed to use the
degree of skill used under similar circumstances by members of his profession;” (3)
“repeatedly abused the professional trust of the physician-patient relationship for the pur-
pose of engaging in sexual activity;” (4) “lied on his Missouri medical license renewal
application;” and (5) “did not appropriately treat a patient in the course of his duties as
an Emergency Room physician ultimately leading to a patient’s death.” Id. at 2–3.
257. Id. at 3.
258. Id. at 4 (citing ARIZ. REV. STAT. § 32-1401(27)(d) (2013), which involves “com-
mitting a felony, whether or not involving moral turpitude, or a misdemeanor involving
moral turpitude” and ARIZ. REV. STAT. § 32-1401(27)(o) (2013), which involves “action
that is taken against a doctor of medicine by another licensing or regulatory jurisdiction
due to that doctor’s . . . medical incompetence or for unprofessional conduct as defined
by that jurisdiction and that corresponds directly or indirectly to an act of unprofessional
conduct . . . .”).
259. Id. at 5.
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ties will remain.  These are the individuals who should face vigorous
criminal prosecution; and as these prosecutions become more preva-
lent, they will serve as eye-opening deterrents from gray market activity
in that state and within that profession more broadly.
The national market will benefit from coordination among states
in the consistent enforcement of state laws with similar provisions
aimed at crippling the gray market for biologics.  Otherwise, bad actors
will relocate to states with less scrutiny and continue to feed the illicit
supply.
Florida and Georgia provide a telling example, in the prescription
opioid context, of criminal actors relocating to states where federal laws
are less rigorously enforced and state laws are less aggressive in protect-
ing public health and safety.260  Florida successfully reduced prescrip-
tion opioid diversion, abuse, and resultant overdose deaths thanks to a
combination of enforcement of federal and state controlled substance
laws and legislative actions designed to improve public health and safety
by cracking down on pill mills and rogue prescribers.261  Measures
included professional education requirements, revoking licenses to dis-
pense controlled substances,262 charging prescribers under the CSA, or
charging the most extreme physicians with murder when their patients
died of overdoses.263  Pam Bondi, Florida’s Attorney General, described
such physicians as “drug dealers wearing white coats.”264  As a result of
Florida’s success, bad actors relocated to Georgia, leading to a surge in
pill mills in that state.265  Such consequences can be avoided by prop-
erly enforcing federal and state pharmaceutical commerce laws and
implementing new health and safety requirements, including profes-
sional education mandates, consistently throughout the states.
B. Best Practices for Health Care Organizations
The health care industry must be made aware of the dangers of
gray market biologics. Health care providers should implement best
policies and practices regarding gray market biologics, as they have
done with prescribing opioids.  For instance, various patient advocacy
260. Florida Combats Prescription Drug Abuse with Laws and Enforcement, DRUGFREE.ORG
(Apr. 8, 2013), http://www.drugfree.org/join-together/community-related/florida-com-
bats-prescription-drug-abuse-with-laws-and-enforcement [hereinafter Florida Combats Pre-
scription Drug Abuse].
261. See FLA. DEP’T OF LAW ENFORCEMENT, DRUGS IDENTIFIED IN DECEASED PERSONS
BY FLORIDA MEDICAL EXAMINERS: 2012 INTERIM REPORT ii (Mar. 2013), http://www
.fdle.state.fl.us/Content/getdoc/9c4df7c2-4b07-4f7a-acfb-6461719c0e44/2012-interim-
drug-reportFINAL.aspx (showing a decrease in overdose deaths from 2011 to 2012).
262. Florida Combats Prescription Drug Abuse, supra note 260.
263. FLA. OFFICE OF DRUG CONTROL, FLORIDA’S PRESCRIPTION DRUG DIVERSION AND
ABUSE ROADMAP 2012-2015 17 (Apr. 2, 2012), http://myfloridalegal.com/webfiles.nsf/
WF/KGRG-8T8L5K/$file/PrescriptionDrugDiversionAndAbuseRoadmap.pdf.
264. Lizette Alvarez, Florida Shutting ‘Pill Mill’ Clinics, N.Y. TIMES (Aug. 31, 2011),
http://www.nytimes.com/2011/09/01/us/01drugs.html?pagewanted=all.
265. Timothy W. Martin, Florida “Pill Mill” Crackdown Sets Off a Rush into Georgia,
WALL ST. J., Dec. 25, 2012, http://online.wsj.com/news/articles/SB10001424127887324
478304578173341194754984.
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groups, hospitals, and practice groups have voluntarily adopted opioid
safe prescribing and treatment monitoring guidelines.  Similarly, when
dealing with potential gray market biologics, health care administrators
should consult with the institution’s risk management and legal team in
order to understand the differences between a legal and an illegal dis-
tribution operation and establish internal policies based on best prac-
tices.266  Purchasers must plan ahead to determine the impact on
scheduling treatments and the availability of other agents in the same
class, so they are not left without solutions when a drug shortage hap-
pens.267  Johns Hopkins Hospital, for example, has developed a strict
policy against purchasing prescription drugs on the gray market,
regardless of whether there is a shortage.268  At Hopkins, a coordinated
task force of clinicians, pharmacists, drug purchasers, and other stake-
holders meets frequently to discuss current and future drug shortages
based on the volume of patients.269  Given that tracking the availability
of prescription drugs is a time-consuming task, some hospitals have
hired technicians to track and follow medications on backorder.270
The cost of tracking outweighs the cost of adverse events caused by
harmful gray market drugs.
Before making a purchase, the pharmacy director should confirm
with the state board of pharmacy that the seller is a properly licensed
distributor.271  If the distributor is not properly licensed, then no
purchase should be made.  Additionally, no purchase should be made
unless the shipment contains an entire transaction history for the medi-
cations.272  A legitimate drug cannot be profitably sold more than once
or twice, so if the transaction history reflects three or more preceding
sales, the shipment should be declined.273
Providers should exhibit due diligence in purchasing high-quality
pharmaceuticals, and they must thoroughly inspect products to ensure
that they are, in fact, what they are purported to be.274  If purchasing
from a new supplier, providers should compare and scrutinize the pack-
age, label, and contents; and should not use a drug if there is any cause
for suspicion or concern.  A drug is suspicious, for example, if a label
contains a foreign language or lacks “for Rx use only,” or the package
266. See CHERICI ET AL., supra note 74, at 5–6. R
267. Greg Rienzi, Essential Drugs, Short Supplies, JOHNS HOPKINS MAG. (June 3, 2013),
http://hub.jhu.edu/magazine/2013/summer/drug-shortage-task-force.
268. Id.
269. Id.
270. See Jaimy Lee, Providers Fuel Gray Market: Some Sell While Others Buy During Drug
Shortage, MODERN HEALTHCARE (Sept. 5, 2011), http://www.modernhealthcare.com/arti
cle/20110905/MAGAZINE/309059980.
271. See CHERICI ET AL., supra note 74, at 6. R
272. See id.
273. Ling, supra note 249, at 157.
274. Marv Shepherd, Tips for Pharmacists in Detecting Counterfeit Medications, CURRENT
CONCEPTS IN PHARMACY MGMT., U. OF ARIZ. HEALTH SCI. CTR., Summer 2011, available at
http://www.ccpharm.com/01_counterfeit_meds.php.
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appears tampered with.275  Practitioners can also check manufacturers’
websites for alerts describing how to identify misbranded drugs.276  For
example, when the manufacturer of botulinum toxin type A became
aware of gray market distribution of its product, the company provided
a video for botulinum toxin type A purchasers, which described packag-
ing conventions that distinguished real botulinum toxin type A from its
illegal counterparts.277
Providers must understand and account for the risks to their prac-
tice and the risks to the patients they serve by seeking legal and risk
management counsel.278  They must (1) develop and widely communi-
cate policies for decisions regarding purchases, (2) confirm with the
state board of pharmacy or department of health that a distributor is
appropriately licensed and not subject to any current investigations,
and (3) request drug history documents.279  They should keep records
of sellers they have refused to do business with and the reasons why.280
Finally, they should report any suspicious supplier to the appropriate
local, state, and national authorities and to the product
manufacturer.281
C. Consumer Awareness
Consumers must be made aware of the harms involved in taking
gray market biologics. Yet, recent federal and state actions have yielded
contradictory messages.
1. Consistent Messages to Consumers
Although it is illegal for foreign pharmacies to distribute drugs to
individuals in the United States for personal use in most circumstances,
the FDA has adopted a narrow policy exception in which it will allow
consumers to import non-FDA-approved medications.282  For the
exception to apply, all of the following factors must be met:
1) The drug is for a serious condition for which effective treat-
ment is not available in the United States;
2) There is no commercialization or promotion of the drug to
U.S. residents;
3) The drug is considered not to represent an unreasonable risk;
275. Press Release, Premier Healthcare Alliance, Drug Shortages Leading to Price
Gouging, Possible Safety Issues, According to Research (Aug. 16, 2011), http://www
.reuters.com/article/2011/08/16/idUS172348+16-Aug-2011+BW20110816.
276. McKenzie & Kelly, supra note 140.
277. Id.
278. Press Release, Premier Healthcare Alliance, supra note 275.
279. Id.
280. Id.
281. Id.
282. ABOUT FDA, Is It Legal for Me to Personally Import Drugs?, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194904.htm (last
updated Nov. 18, 2014).
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4) The individual importing the drug verifies in writing that it is
for his or her own use, and provides contact information for the
doctor providing treatment or shows the product is for the contin-
uation of treatment begun in a foreign country; and
5) Generally, not more than a three-month supply of the drug is
imported.283
Giving the impression that importation of Canadian pharmaceuti-
cals from online pharmacies may be acceptable, Congress enacted
amendments to the FDCA in 2001 and 2003, entitled the Medicaid Pre-
scription Drug, Improvement, and Modernization Act (“MMA”), which
allowed limited importation of certain prescription drugs from Canada
by pharmacists, wholesalers, and consumers.  The MMA required the
Secretary of HHS to first certify that the importation would “pose no
additional risk to the public’s health and safety.”284  All four of the Sec-
retaries of HHS who have served since the amendment was enacted
have declined to make the requisite certifications.285
Policies like these lead consumers to believe that purchasing medi-
cations online, including biologics, is not risky.  For instance, in 2006, a
group of consumers and organizations joined together to bring a class
action anti-trust lawsuit against various pharmaceutical manufacturers
under the Clayton Act.286  They argued that the drug manufacturers
unlawfully conspired to suppress the importation of Canadian prescrip-
tion drugs for personal use by engaging in “a concerted course of con-
duct designed to prevent brand name prescription drugs purchased
from Canadian pharmacies from entering the United States” and caus-
ing American consumers to pay higher drug prices.287
In In re Canadian Import Antitrust Litigation, the Eighth Circuit
affirmed the district court’s grant of a motion to dismiss, finding that
the FDCA prohibits virtually all importation of prescription drugs into
the United States by individual consumers for personal use.288  Such
283. Id.
284. 21 U.S.C. § 384(l)(1)(A) (2012).
285. 21 C.F.R. §§ 200–369 (2002); In re Canadian Import Antitrust Litig., 470 F.3d
785, 790 (8th Cir. 2006) (stating that all three secretaries between 2001 and 2006
declined to make this certification. This case was decided in 2006, before current Secre-
tary Kathleen Sebelius took the position.  Secretary Sebelius also has not made the certifi-
cation). The Secretaries who declined to make this certification include Donna Shalala
(1993–2001), Tommy G. Thompson (2001–2005), Michael O. Leavitt (2005–2009), and
Kathleen Sebelius (2009–present).
286. In re Canadian Import Antitrust Litig., 470 F.3d at 787.
287. Id. at 788. The plaintiffs argued that the defendant drug companies engaged
in anticompetitive conduct, including:
1) Requiring Canadian pharmacies to certify that they were not selling prescription
drugs to persons whom the pharmacies knew or should have known were taking the drugs
outside the country,
2) Monitoring orders of Canadian pharmacies and limiting their purchases to histor-
ical levels,
3) Creating “blacklists” of pharmacies that were suspected of selling drugs to Ameri-
can consumers and directing wholesalers not to sell to the blacklisted pharmacies, and
4) Cutting off supplies to wholesalers who did not comply with their policies.
288. Id. at 788–89.
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drugs violate the FDCA because they are predominantly unapproved
new drugs, are misbranded because they are not labeled in accordance
with federal requirements, or are dispensed without a valid prescrip-
tion.289  Many illicit online pharmacies do not require the consumer to
provide a prescription in order to purchase the medication, as is
required by the FDCA.
In particular, the Eighth Circuit ruled that the Canadian prescrip-
tion drugs at issue were misbranded.290  Prescription drugs dispensed
by Canadian pharmacies are labeled “Pr,” as opposed to the required
“Rx only.”291  Whereas the plaintiffs argued that the Canadian symbol
was the “functional equivalent” of “Rx only,” the court found that fed-
eral law does not provide for functional equivalence in labeling.292
Given that foreign labeling differs from domestic labeling, approval
granted to a specific manufacturer for a particular product to be distrib-
uted in the United States does not constitute approval of another
drug—even one with the same chemical composition—that is distrib-
uted in Canada with different labeling, and then imported into the
United States.293  This precise labeling requirement is a manifestation
of Congress’s intent to create a “closed system” designed to guarantee
safe and effective drugs for consumers in the United States.294  There-
fore, it is per se illegal to import Canadian drugs into the United States
for personal use, or drugs from any other country for that matter,
except in cases that fit the narrow exception created by the FDA.295
Despite the ruling in In re Canadian Import Antitrust Litigation and the
decision not to certify importation under the MMA, the FDA has been
unable to adequately enforce the legal prohibition on personal impor-
tation of foreign drugs.296
State courts, nevertheless, have upheld the personal right to
choose what may be a “suicidal medical course,”297 including choosing
to use non-FDA-approved medications imported from abroad and the
right to use a nontoxic substance in connection with one’s own per-
sonal health care.298  The issue of toxicity begs the question that Con-
289. Id. (citing 21 U.S.C. §§ 352, 353(b)(1), 355 (2006)).
290. Id. at 789.
291. Id.
292. Id.
293. Id. at 790.
294. Id.
295. Id. at 790–91.  While it is true that no federal statute by its express terms bans
importation of prescription drugs from Canada, such an explicit country-by-country pro-
hibition is unnecessary to accomplish the task. By creating [a] comprehensive regulatory
system . . . , Congress has effectively precluded importation of these drugs absent the sort
of special authorization contemplated by 21 U.S.C. § 384.
296. Id. at 791.
297. People v. Privitera, 141 Cal. Rptr. 764, 770 (Ct. App. 1977); Matter of Erickson
v. Dilgard, 252 N.Y.S.2d 705 (Sup. Ct. 1962); Schloendorff v. Soc’y of N.Y. Hosp., 105 N.E.
92 (N.Y. 1914).
298. Privitera, 141 Cal. Rptr. at 783, rev’d, 591 P.2d 919, 945 (Cal. 1979) (finding
that although the FDA had not approved a certain cancer medication yet, the patient still
has “the choice of ‘state sanctioned’ treatment by the doctor or no treatment from
the doctor at all”); Rutherford v. United States, 438 F. Supp. 1287, 1301 (W.D. Okl. 1977).
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gress has answered through the FDCA’s drug approval and labeling
requirements.
At least one state has enacted its own legislation explicitly permit-
ting importation of prescription drugs for personal use.  On June 27,
2013, Maine became the first state to legalize importation of prescrip-
tion medications from pharmacies in Canada, the UK, New Zealand,
and Australia (the “Importation Law”).299  According to Maine’s
Importation Law, a licensed retail pharmacy in one of those countries
may export prescription drugs to a resident of Maine for the resident’s
personal use.300  Consumers who take prescription drugs shipped into
Maine by foreign pharmacies pursuant to the Importation Law do not
benefit from the quality and safety controls put into place by the federal
government.301  What’s more, consumers in the United States tend to
be particularly trusting of online pharmacies purporting to be Cana-
dian pharmacies even though many of these pharmacies are actually
located in countries other than Canada and sell drugs that are not man-
ufactured or approved for sale in Canada.302
Importation and re-importation are prohibited under the FDCA
and PDMA, and state laws that are contrary send a mixed message to
citizens, propagating a notion that drugs from foreign countries are as
safe and effective as medications approved and labeled for use in the
United States.303  Furthermore, such state laws are preempted by fed-
eral law under the Supremacy Clause of the US Constitution.  Pursuant
to the preemption doctrine, federal law preempts state law if it contains
“express” language overruling state law or to the extent that the laws
conflict, whereby following the state law would violate the federal
law.304  The Maine law is preempted by the MMA, which does not allow
for the importation of prescription drugs from Canada by pharmacists
until the Secretary of HHS first certifies that the importation would
299. Julie Rovner, Maine Once Again Allows Mail-Order Canadian Drugs to Cut Costs,
NPR (June 27, 2013, 5:00 PM), http://www.npr.org/blogs/health/2013/06/27/1963251
73/maine-once-again-allows-mail-order-canadian-drugs-to-cut-costs.
300. ME. REV. STAT. tit. 32, § 13731(1)(B) (2013).
301. Complaint at 1, Ouellette v. Mills, No. 1:13-CV-00347-NT, 2014 WL 1975438
(D. Me. May 15, 2014).
302. Deceptive Practices, supra note 93. R
303. Save Money by Ordering Drugs from Canada? Not So fast, CONSUMER REPORTS NEWS
(Oct. 27, 2011, 6:08 AM), http://www.consumerreports.org/cro/news/2011/10/save-
money-by-ordering-drugs-from-canada-not-so-fast/index.htm (noting that most Canadian
websites are not actually Canadian pharmacies after all).
304. Pac. Gas & Elec. Co. v. State Energy Res. Conservation & Dev. Comm’n, 461
U.S. 190, 203–04 (1983) (noting that Congress may, if acting pursuant to its Constitu-
tional authority, preempt state law “by so stating in express terms”).  In addition, there
are certain areas of the law where the federal interest deemed to have preempted the
entire “field” of regulations. Id.  However, despite the existence of some federal laws
regulating prescription drugs, the states have broad authority to regulate practices
impacting the health of their citizens. See United States v. Lopez, 514 U.S. 549, 594
(1995) (Thomas, J., concurring) (“That the internal commerce of the States and the
numerous state inspection, quarantine, and health laws had substantial effects on inter-
state commerce cannot be doubted. Nevertheless, they were not ‘surrendered to the gen-
eral government.’”); see also Barnes & Arndt, supra note 48 (noting that both the federal R
government and the states regulate prescription drugs concurrently).
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“pose no additional risk to the public’s health and safety.”305  This certi-
fication has yet to happen. Moreover, the Importation Law is an
encroachment by the state of Maine on the federal government’s exclu-
sive power to regulate foreign commerce, as affirmed by the US
Supreme Court in 2005 in its Gonzalez v. Raich decision.306
States should not follow Maine’s lead in allowing importation of
pharmaceuticals, including gray market biologics, from online “Cana-
dian” pharmacies.  Instead, states should crack down on entities dealing
in gray market biologics, as states like Florida have done with entities
that divert controlled substances.  States must provide clear messages to
consumers regarding the dangers of gray market biologics as they have
with the dangers of controlled substance diversion and abuse.
In another case in which opioid diversion and gray market activity
overlap, Texas’s Attorney General prosecuted pharmacist Rakesh Jyoti
Saran for his elaborate involvement with a rogue internet pharmacy
scheme that involved gray market diversion of controlled substances to
drug-seekers.307  Mr. Saran operated twenty-three Texas-incorporated
pharmacies and purchased various controlled substances at significantly
discounted prices by fraudulently claiming his purchases were for insti-
tutional pharmacies.308  He then sold the controlled substances illegally
to individuals without valid prescriptions at four times the cost of mar-
ket price.309  He played an integral role in providing hydrocodone,
alprazolam, and promethazine cough syrup with codeine to individuals
who illegally sold the drugs “on the street.”310  Mr. Saran pleaded guilty
to conspiracy to commit health care fraud, two counts of mail fraud,
and one count of conspiracy to distribute controlled substances.311  He
was sentenced to twelve years in federal prison and ordered to pay $68
million in restitution.312  This is a case of excessive wrongdoing, in
which the penalty should be steep. Consumers must be protected from
this kind of behavior.
More attorney generals and state prosecutors should take actions
against rogue pharmacies that traffic in diverted medications and jeop-
ardize public health and safety.  It is important that professionals and
consumers receive a consistent message about the dangers of drugs that
circulate outside the lawful distribution chain.  Authorizing the illegal
importation of drugs for personal use, as Maine has done, blurs this
305. 21 U.S.C. § 384(l)(1)(A) (2012).
306. Complaint at 2, Ouellette v. Mills, No. 1:13-CV-00347-NT, 2014 WL 1975438
(D. Me. May 15, 2014); see Gonzalez v. Raich, 545 U.S. 1, 9 (2005) (holding that federal
law that criminalizes cannabis use is a valid exercise of federal power and therefore super-
sedes California state law decriminalizing cannabis use in medical treatment).
307. Press Release, U.S. Dep’t of Justice, Lead Defendant in Health Care Fraud and
Rogue Internet Pharmacy Scheme Sentenced to 12 Years in Federal Prison and Ordered
to Pay $68 Million in Restitution (Dec. 11, 2009), http://www.justice.gov/usao/txn/Press
Rel09/saran_sen_pr.html.
308. Id.
309. Id.
310. Id.
311. Id.
312. Id.
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important message, undermines federal supremacy of laws, and places
patient safety at risk.
1. Consumer Awareness Campaign
One of the most important players in reducing the demand for
gray market pharmaceuticals is the consumer.  Unfortunately, many
appear unaware of the dangers that lurk in the prescription drug supply
chain.  For example, a survey of US patients found that fifteen percent
of respondents had purchased drugs online.313  However, the vast
majority, ninety-three percent, of these respondents who had pur-
chased prescription drugs online never suspected that the products
might be counterfeit.314  Furthermore, many adults lack basic knowl-
edge regarding the illegality of pharmaceutical importation, as demon-
strated by one survey in which forty-five percent of consumer
respondents perceived drug importation practices to be legal, while
thirty-three percent were unsure.315  Even if patients are aware of the
illegality of importing prescription drugs, many patients still look to
purchase their medications at lower cost from foreign or illegitimate
online suppliers.316  It is not only important that patients learn to rec-
ognize the safety concerns associated with purchasing drugs from the
gray market via the internet or a trip to another country, but that they
also understand that even the prescriptions bought from a local phar-
macy or administered by their health care provider are at risk of having
been adulterated if purchased on the gray market.
Patients should closely examine the appearance of the package
and drug each time they receive it and compare it to the original manu-
facturer’s packing available online.317  Patients should also feel and
take note of the drug’s taste or the way the injection site feels.318  They
must evaluate how their bodies react over the course of the treatment
and consult with a pharmacist or physician on what they should expect
to feel.319  If something feels wrong after the administration of the pre-
scription, patients should immediately write down their symptoms and
call their physician.320  Individuals should report any quality concerns
to their state board of pharmacy, the manufacturer, and the FDA’s
Drug Quality Reporting System (“DQRS”), where it will be classified
and should be investigated.321
313. Brian A. Liang, A Dose of Reality: Promoting Access to Pharmaceuticals, 8 WAKE
FOREST INTELL. PROP. L.J. 301, 326 (2008).
314. Id.
315. Monali J. Bhosle & Rajesh Balkrishnan, Drug Reimportation Practices in the United
States, 3 THERAPEUTICS & CLINICAL RISK MGMT. 41, 43 (2007).
316. See supra Part III.
317. An 8-Step Checklist for Medicine Safety, P’SHIP FOR SAFE MEDS., http://www.safe
medicines.org/consumer/SAFEDRUG.pdf (last visited Mar. 12, 2014).
318. Id.
319. Id.
320. Id.
321. FDA, REPORTING DRUG QUALITY PROBLEMS 2 (July 2009), http://www.fda.gov/
downloads/ForConsumers/ConsumerUpdates/UCM173143.pdf.
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As a result of the seemingly endless number of illegitimate online
pharmacies, the National Association of Boards of Pharmacy (“NABP”)
has created the “Verified Internet Pharmacy Practice Sites” (“VIPPS”)
program.322  If individuals insist on purchasing online medication, they
should only do so from VIPPS accredited sites.  In order for an online
pharmacy to be VIPPS accredited to dispense pharmaceuticals, it must
comply with state licensing and inspection requirements.323  VIPPS
pharmacies must also demonstrate compliance with other criteria,
including authentication and security of prescription orders, adherence
to a quality assurance policy, and meaningful consultation between
patients and pharmacists.324  Currently only thirty-five online pharma-
cies have been VIPPS-approved as safe and legitimate.325  This is a far
cry from the hundreds of pharmacies that citizens are presented with
when they utilize a search engine, making the process of ordering
online much less intimidating.
V. CONCLUSION
Biologics are a significant medical advancement that improves the
health of countless consumers.  However, if improperly stored, handled
incorrectly, expired, or diluted, they can become unsafe, ineffective, or
both.  Given that there is no guarantee of the safety and efficacy of gray
market medications, physicians and pharmacists should never dispense
or administer gray market biologics.
Yet, gray market activity is widespread in the health care industry.
Bad actors exist throughout the entire system of distribution, but physi-
cians and pharmacists can prevent dangerous, misbranded biologics
from reaching patients.  Those physicians and pharmacists who partici-
pate in the gray market, acting with knowing intent or mere negligence
or ignorance, may face criminal liability under various legal doctrines.
Given a purported lack of federal resources to adequately prosecute
gray market participants, states must step in, not only to enact legisla-
tion or regulations requiring professional education, but also to reha-
bilitate or sanction negligent licensees.  Once properly educated, the
physicians and pharmacists with good intentions will know better than
to purchase or dispense gray market biologics, and intentional wrong-
doers will be isolated for vigorous prosecution.  A strong deterrent mes-
sage to would-be copycats will reduce the proliferation of the gray
market for biologics.  Additionally, health care groups must adopt best
practices, and consumers must be made aware of the dangers of gray
market biologics.  In doing so, the risks of gray market biologics may
decrease in a manner analogous to the risks of diverted controlled
substances.
322. See generally Verified Internet Pharmacy Practice Sites (VIPPS), NAT’L ASS’N OF BDS.
OF PHARMACY (Mar. 3, 2014), http://vipps.nabp.net/ (last visited Aug. 10, 2013).
323. Id.
324. Id.
325. See Find a VIPPS Online Pharmacy, NAT’L ASS’N OF BDS. OF PHARMACY, http://
www.nabp.net/programs/accreditation/vipps/find-a-vipps-online-pharmacy/ (last visited
Aug. 10, 2013).
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FIGURE 1. EXAMPLE OF THE TRADITIONAL SUPPLY CHAIN.
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FIGURE 2. EXAMPLE OF A GRAY MARKET CHAIN OF DISTRIBUTION.
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FIGURE 3. GRAY MARKET SOLICITATION FROM GALLANT
PHARMACEUTICALS
\\jciprod01\productn\N\NDE\29-2\NDE203.txt unknown Seq: 48 20-APR-15 16:47
